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ABSTRACT OF THE DISSERTATION
A High-Content Screen Identifies HSP90 as a Component of Axon Injury Signaling
by
Scott L. Karney-Grobe
Doctor of Philosophy in Biology and Biomedical Sciences
Developmental, Regenerative, & Stem Cell Biology
Professor Aaron DiAntonio, Chair

Axons are unique compartments of neurons that extend tremendous distances throughout
the body. Neurodegenerative or traumatic damage to axons destroys neuronal function and thus
necessitates axonal repair. Mammalian peripheral neurons can regrow their axons following injury,
providing a robust system to study the molecular mechanisms of axon regeneration. Injury induces
a large transcriptional program that drives regeneration. While many regeneration-associated
genes are known, the mechanisms by which injury activates them are less well understood.
Identification of new injury signals has been limited by in vivo approaches. To address this
challenge, I developed and performed a loss-of-function pharmacological screen in cultured adult
mouse sensory neurons for proteins required to activate this program. Well-characterized
inhibitors were present as injury signaling was induced, but were removed before axon outgrowth
to identify molecules that block induction of the program. The top hits were inhibitors to heat
shock protein 90 (HSP90), a chaperone with no known role in axon injury. HSP90 inhibition
blocks injury-induced activation of several regeneration-associated genes and proteins. These
phenotypes mimic loss of the pro-regenerative MAP3K, dual leucine zipper kinase (DLK), a
critical neuronal stress sensor that drives axon degeneration, axon regeneration, and cell death.
ix

HSP90 is an atypical chaperone that promotes the stability of signaling molecules. In neurons,
HSP90 and DLK demonstrate the two hallmarks of a HSP90-client relationship: 1) HSP90 binds
DLK and 2) HSP90 inhibition leads to rapid degradation of existing DLK protein. Thus, this
dissertation demonstrates that HSP90 chaperones DLK and is required for DLK functions,
including pro-regenerative axon injury signaling. Further, this work introduces a high-content,
unbiased method to identify novel components of axon injury signaling.

x

Chapter 1: Introduction
The magnificent architecture of neurons has provided scientists with unending cell biology
questions. A neuron consists of a cell body (or soma), highly-arborized dendrites, and, commonly,
one axon. The axon is a specialized compartment that transmits action potentials from the cell
body to synaptic targets such as dendrites or muscles. Axons can extend extremely long distances,
often on the order of meters in larger organisms such as humans (Misgeld and Schwarz, 2017).
Neurons are also post-mitotic, a characteristic that is simultaneously fascinating and problematic.
In higher organisms, including mammals, most neurons generated during development remain the
only neurons throughout life. This means that some neurons live for over 100 years. Unfortunately,
the inability to self-renew presents neurons with an extreme challenge if they are damaged. Due
to its length, the axon is the most vulnerable compartment of a neuron and can be injured by
internal and external events, including physical trauma, neurodegenerative disease, or
microtubule-disrupting chemotherapies (Farley and Watkins, 2018). These injuries cause various
forms of nervous system failure, such as cognitive decline, loss of sensation, locomotion
defects/paralysis, or death. Thus, these axonopathies demonstrate the dire need for axon
regeneration to restore neural function. Mammalian central nervous system (CNS) neurons in the
adult brain and spinal cord are unable to regenerate their axons after injury. Fortunately, peripheral
nervous system (PNS) neurons retain an intrinsic ability to regenerate their axons. Thus,
mammalian PNS neurons provide a unique system to dissect the molecular mechanisms of axon
regeneration. In addition to the therapeutic benefits, studying the axon regeneration paradigm
provides unique insights into the cell biology of neuronal homeostasis. Here, I will review the
current understanding of axon regeneration and the tools used to study this process. Moreover, I
1

will frame this information around the central questions of my dissertation: How does injury
induce PNS axon regeneration, and can we identify new components of injury signaling using an
unbiased, high-content method?

1.1 Overview of Axon Regeneration
The ultimate goal of axon regeneration is to restore synaptic connections to preserve
nervous system function. It has been known for some time that the nervous system, particularly in
mammals, is fragile and requires active maintenance throughout an organism’s life (Ramon y
Cajal, 1928). Indeed, in the early 1900s, Ramon y Cajal built upon numerous predecessors to
pioneer an in-depth characterization of mammalian axon regeneration at the anatomical level.
After a detailing of the regenerative success in sensory neurons, he observed abortive repair in
injured CNS neurons, including those of the cerebellum, spinal cord, and optic nerve. He agreed
with his predecessors that a primary goal in neurology is “to ascertain in virtue of what perturbatory
conditions this process of axonic restoration, which is so active and rapid in peripheral nerves,
break down lamentably in nerve centres.” (Ramon y Cajal, 1928). Decades later, neurologists
began to observe that chromatolysis, the dissolution of ER-based Nissl bodies, was not just a
passive consequence of axon injury. Chromatolysis was hypothesized to be a peripheral neuronal
soma undergoing massive hypertrophy, alterations in protein synthesis, and RNA production
(Ducker et al., 1969). These were the first clues to suggest that regeneration was an active, intrinsic
process initiated by the soma in response to axonal trauma. Modern molecular biology and genetic
tools have since enabled neuroscientists to dissect the molecular mechanisms of axon injury and
the neuron-intrinsic regenerative response (He and Jin, 2016; Mahar and Cavalli, 2018).

2

1.1.1 Peripheral neurons
A popular neuron used to study axon regeneration is that of the dorsal root ganglion (DRG).
DRG neurons have pseudounipolar axons, with a peripheral branch extending to sensory organs
and a central branch innervating the spinal cord. In the same neuron, the peripheral axon
regenerates, but the central axon does not, providing a convenient system of study. When a
peripheral axon is injured, there is an immediate local response at the injury site, followed by a
global response in the cell body. Disruption of the axonal membrane leads to a massive increase
in Ca2+ that travels in a retrograde wave to trigger intracellular Ca2+ release in the cell body (Bradke
et al., 2012). Within minutes to hours, the cell seals its membrane with a multivesicular patch and
rectifies membrane potential by re-balancing Ca2+ concentration (Bradke et al., 2012). In less than
an hour, distal microtubule and actin networks depolymerize in parallel to the Ca2+ wave (Bradke
et al., 2012). In the axon proximal segment, a growth cone and limited axon sprouting are initiated
immediately after Ca2+ recovery when microtubules polarize, actin networks form exploratory
lamellipodia, and raw materials arrive via anterograde transport as well as local synthesis to
construct new axonal membrane (Bradke et al., 2012). Over several days, the axon distal segment
demyelinates, undergoes programmed Wallerian degeneration, and is cleared by macrophages and
Schwann cells (Christie and Zochodne, 2013; Ducker et al., 1969; Liu et al., 2011).
Concurrent with this local response, injury signals are retrogradely transported to the cell
body and upregulate regeneration-associated genes (RAGs) and protein synthesis (Ducker et al.,
1969; Liu et al., 2011; Mahar and Cavalli, 2018). This gene network is termed the pro-regenerative
program and functions to build and extend new axon. Several well-studied proteins, such as
growth-associated protein 43 (GAP-43), cytoskeletal-associated protein 23 (CAP-23), and Small
proline-rich repeat protein 1A (SPRR1A) are synthesized and transported to the injury site to
3

facilitate growth cone formation and neurite outgrowth, and serve as markers for the regeneration
program (Christie and Zochodne, 2013; Mason et al., 2002; Tedeschi, 2011). Actin and - and
III-tubulin subunits are also upregulated to contribute to axon growth (Leclere et al., 2007). While
the local axonal response initiates within minutes, RAGs are upregulated on the order of hours to
days (Pan et al., 2003; Smith and Skene, 1997). Indeed, RNA Pol II inhibitors can block neurite
elongation, a late stage event, but not growth cone formation, which occurs soon after injury (Smith
and Skene, 1997). Thus, transcription of new components is not required for the local injury
response, but is required for the subsequent robust axon regrowth (Saijilafu et al., 2013). The goal
of my dissertation is to identify new components of axon injury signaling to improve our
understanding of how PNS neurons induce the pro-regenerative program.

1.1.2 Central neurons
CNS neurons exhibit poor regeneration due to extrinsic and intrinsic impedances. In
response to axotomy, most CNS neurons seal their distal stump, but form a “frustrated growth
cone”, or retraction bulb (Bradke et al., 2012). Regeneration does not occur, the cell atrophies and
eventually undergoes apoptosis (Ducker et al., 1969; Liu et al., 2011). It is thought that
regeneration opposes apoptosis and, while regeneration perseveres in the PNS, CNS neurons
default to apoptosis (Watkins et al., 2013). Following injury, degenerating distal nerve stumps
contain myelin debris, such as myelin-associated glycoprotein, that actively block regeneration
(Liu et al., 2011). In the PNS, Schwann cells and macrophages clear this inhibitory environment
via phagocytosis (Christie and Zochodne, 2013). This, however, does not occur in the CNS. It was
originally hypothesized that this inhibitory environment was the primary mechanism behind failed
CNS axon regeneration. Indeed, some CNS axons can grow through a peripheral nerve graft, yet
the response is limited (Liu et al., 2011). Thus, there is more to the story than the inhibitory
4

environment: CNS neurons lack intrinsic regenerative mechanisms. Indeed, spinal cord axons,
despite the presence of a peripheral nerve graft, fail to regenerate past the lesion site and do not
upregulate RAGs such as Gap43 and Cap23 (Mason et al., 2002; van Kesteren et al., 2011). This
intrinsic failure of CNS axons to regenerate stems from the inability to activate pro-regenerative
molecules in addition to the presence of anti-regenerative molecules that impair regrowth (He and
Jin, 2016; Sekine et al., 2018). For example, signal transducer and activator of transcription 3
(STAT3) and mammalian target of rapamycin (mTOR) are both pro-regenerative molecules
activated in injured peripheral neurons (Abe et al., 2010; Lee et al., 2004). Injury to a CNS axon,
however, does not induce STAT3 (Bareyre et al., 2011). Further, in CNS neurons, these two
molecules are inhibited by their respective negative regulators, suppressor of cytokine signaling
(SOCS3) and phosphatase and tensin homolog (PTEN) (Liu et al., 2010; Smith et al., 2009).
Indeed, relieving one or both of these brakes in the CNS promotes modest central axon
regeneration (Park et al., 2010; Park et al., 2008; Smith et al., 2009; Sun et al., 2011).
Recent work has identified a possible mechanism by which CNS neurons appear to
preferentially activate anti-regeneration molecules: age-related developmental decline in
regenerative capacity. For example, several members of the Kruppel-like factor (KLF) family of
transcription factors drive or repress axon outgrowth during development in retinal ganglion cells
(RGCs). Anti-regenerative KLFs are upregulated in post-natal mice, while pro-regenerative KLFs
are downregulated over the same period (Moore et al., 2009). In RGCs, the anti-regenerative KLF4
suppresses the pro-regenerative STAT3, demonstrating an intersection between these two
regeneration-associated pathways (Qin et al., 2013).
In sum, these data demonstrate that CNS neurons actively suppress their regenerative
ability, and perhaps more importantly, that these inhibitions can be partially lifted with the proper
5

molecular tools. Thus, continued study of anti-regenerative molecules in the CNS and proregenerative signals in the PNS is crucial to forming a complete approach to foster nerve repair.
In the following sections, I will discuss the molecular mechanisms of injury signaling and how our
understanding of such signals can provide us with approaches to induce the regeneration program.

1.2 Intrinsic molecular mechanisms of peripheral axon regeneration
1.2.1 Axon injury signaling
Peripheral neurons can sense axonal injury and reprogram themselves into a proregenerative state. How do neurons detect such a trauma? Injury signaling is a multi-stage process
that initiates locally at the injury site and converges on gene expression in the cell body (Abe and
Cavalli, 2008; Rishal and Fainzilber, 2010). One of the earliest events following disruption of the
axonal membrane is the influx of Ca2+. In both C. elegans and mammalian neurons, this Ca2+ wave
is propagated to the soma by retrogradely depolarizing voltage-gated sodium channels (GhoshRoy et al., 2010; Mandolesi et al., 2004). The result is Ca2+-induced Ca2+ release to provide
persistent Ca2+ signaling to downstream messengers. One important target pathway of injuryinduced Ca2+ signaling is PKCµ/HDAC5 (protein kinase C/histone deacetylase 5). PKCµ responds
to Ca2+ to phosphorylate HDAC5, which deacetylates tubulin to promote regeneration (Cho and
Cavalli, 2012). Moreover, phospho-HDAC5 exits the nucleus, allowing histone acetylation to
foster the transcriptional upregulation that occurs with injury (Cho et al., 2013). In C. elegans, this
same Ca2+ wave activates the pro-regenerative kinase, DLK (Yan and Jin, 2012). We will further
discuss DLK in detail below. Thus, Ca2+ influx serves as a critical first step of injury signaling that
activates pro-regenerative molecules, some of which epigenetically prime the nucleus for
increased gene expression.
6

Concurrently with ion influx, axon injury destroys the axonal cytoskeleton. Recent work
from our lab has demonstrated that disruption of actin or microtubules triggers injury signaling
(Valakh et al., 2013). Indeed, destabilizing either of these cytoskeletal networks directly via drugs
is sufficient to “injure” DRG neurons and induce the pro-regenerative state (Valakh et al., 2015).
As we will discuss below, DLK signaling appears to be a major pathway that facilitates
cytoskeletal-induced injury signaling. Taken together, it is clear that the neuron can detect multiple
components of a physical trauma in order to drive pro-regenerative signaling.
Following these immediate events, numerous signaling molecules are activated in the axon
and retrogradely transported to the nucleus (Michaelevski et al., 2010; Rishal and Fainzilber, 2010,
2014). For instance, several mitogen-activated protein kinases (MAPKs) are activated in the axon.
cJun N-terminal kinase (JNK) is phosphorylated and attached to vesicles on retrograde dynein
motors via JNK-interacting proteins (JIPs) (Abe et al., 2009; Cavalli et al., 2005). Indeed, phosphoJNK and its upstream MAPKs, such as phospho-MKK4 and phospho-MKK7, can be found
accumulating at the proximal side of the distal stump following a nerve ligation (Lindwall and
Kanje, 2005). Similarly, transcription factors such as STAT3 and locally-synthesized Luman are
activated and attached to retrograde motors (Lee et al., 2004; Ying et al., 2014).
How do these injury signals know where to go? Interestingly, nuclear localization sequence
proteins (NLS) are axonally localized. Upon axon injury, importin β is locally translated and
facilitates binding of NLS peptides to injury signals to drive retrograde transport (Hanz et al.,
2003). Similarly, an intermediate filament, vimentin, is also locally translated to facilitate binding
of phosphorylated ERK to importin β and dynein (Perlson et al., 2005). Thus, locally translated
support proteins facilitate transport of activated signaling molecules.

7

Injury signals converge on a network of transcription factors that drive regenerationassociated genes (Tedeschi, 2011). While some transcription factors, such as STAT3, are
retrogradely transported, others, such as cJun, are localized to the soma and await activation from
retrogradely transported kinases (Lee et al., 2004; Lindwall and Kanje, 2005). cJun is the main
transcription factor target of JNK and is required for PNS axon regeneration (Raivich et al., 2004).
Activating transcription factor 3 (ATF3) is another classically studied pro-regenerative
transcription factor that is induced by JNK signaling and is necessary and sufficient for peripheral
axon regrowth (Lindwall et al., 2004; Seijffers et al., 2006; Seijffers et al., 2007). Recently, the
Cavalli group identified hypoxia-inducible factor 1 (HIF-1α) as a major transcription factor
essential for PNS axon regeneration that is responsible for driving a large portion of the proregenerative gene network (Cho et al., 2015). Numerous other transcription factors drive axon
regeneration, but their discussion is outside the scope of this introduction (Moore and Goldberg,
2011; Smith et al., 2011).
For transcription factors to efficiently drive gene expression, it is necessary for chromatin
to be in an open state. Recently, many groups have shed light on the epigenetic reprogramming
required to activate the pro-regenerative program (Shin and Cho, 2017). Interestingly, DNA in
uninjured DRG neurons is hypoacetylated, an epigenetic modification associated with
heterochromatin. Injury to the peripheral axon, but not the central axon, of a DRG neuron induces
a large increase in acetylated histones (Finelli et al., 2013). Specifically, acetylation is enriched at
the promoters of many regeneration-associated genes. This demonstrates that PNS neurons
actively open their DNA in response to injury in preparation for expressing the pro-regenerative
gene network. In addition to HDAC5, many other histone modifiers are induced by injury. The
histone acetyltransferase p300/CBP-associated factor (PCAF) is a histone writer that is induced by
8

phospho-ERK to acetylate the promoters of regeneration genes (Puttagunta et al., 2014). Similarly,
DNA methylation, a repressive modification, is reduced by ten-eleven translocation
methylcytosine dioxygenase 3 (Tet3) following sciatic nerve injury (Weng et al., 2017).
Interestingly, both PCAF and Tet3 are induced by injury to the peripheral branch but not the central
branch of DRG neurons (Puttagunta et al., 2014; Weng et al., 2017). In sum, many signaling
components converge on the pro-regenerative program to facilitate peripheral axon regeneration.
I will now focus on the main injury signal related to this dissertation, DLK.

1.2.2 DLK
DLK belongs to a unique subfamily of mixed lineage kinases (MLKs), which are MAP
triple kinases (MAP3Ks) responsible for reacting to extracellular stimuli, including stress (Davis,
2000). DLK contains a serine/threonine kinase domain and leucine zipper motifs that facilitate
dimerization (Holzman et al., 1994). DLK was first cloned from developing mouse kidneys but
was subsequently found to be strongly expressed in neurons within the adult brain, spinal cord,
and DRG (Mata et al., 1996). These early studies demonstrated that DLK localizes to the axon and
synapse and can associate with membrane (Mata et al., 1996). DLK responds to cellular stress and
drives MAPK signaling through the MAP2Ks MKK4/7 and the MAPK families of JNK and p38
(Fan et al., 1996; Nihalani et al., 2000). JNKs and p38s subsequently activate transcription factors
to drive the appropriate stress response genes. DLK is an evolutionarily conserved kinase that is
critical for detecting neuronal stress, including axon injury, in C. elegans, Drosophila, and rodents
(Tedeschi and Bradke, 2013).
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DLK and axon regeneration
A genetic screen in C. elegans was the first to implicate DLK as an essential proregenerative kinase. Worms mutant for dlk-1 are unable to form growth cones or regenerate axons
following various forms of axotomy (Hammarlund et al., 2009). Similarly, the fly ortholog of
DLK, Wallenda (Wnd), is necessary for Drosophila axon regeneration (Xiong et al., 2010). The
DLK signaling cascade is conserved in Drosophila, as Wnd is required for a retrograde injury
signal that converges on pro-regenerative JNK activity (Xiong et al., 2010). In C. elegans, DLK
drives regeneration through JNK as well as p38, but it is unclear if this mechanism involves a
retrograde signal (Hammarlund et al., 2009; Nix et al., 2011). In mammals, DLK is required to
induce the pro-regenerative program in peripheral neurons, as axon regeneration fails in both
motor and sensory axons in mice lacking DLK (Shin et al., 2012). Moreover, our lab demonstrated
that mammalian DLK is required for retrograde transport of other injury signals, such as phosphoSTAT3 and phospho-JNK. Indeed, without DLK, these signals accumulate in the injured nerve
and fail to induce their downstream targets in the cell body, such as cJun in the case of phosphoJNK (Shin et al., 2012). Our lab is currently investigating the DLK-dependent transcripts to
identify the portion of the pro-regenerative program for which DLK is responsible.
Regulation of DLK
The importance of DLK for axon regeneration is explicit. Somewhat less clear, however,
is our understanding of the molecular mechanisms of DLK regulation. Early work from the
Holzman group demonstrated that DLK forms homodimers through its unique leucine zippers and
autophosphorylates (Mata et al., 1996; Nihalani et al., 2000). Importantly, overexpression of DLK
is sufficient to drive homodimerization, demonstrating that increased DLK levels are sufficient to
activate DLK. Indeed, the literature reveals that the best understood mechanism for regulating
10

DLK is controlling its abundance. The best-known regulator of DLK abundance is the E3 ubiquitin
ligase, PHR1/highwire/RPM-1, which actively targets DLK for degradation in mice, Drosophila,
and C. elegans (Babetto et al., 2013; Brace et al., 2014; Collins et al., 2006; Nakata et al., 2005).
In Drosophila, highwire (hiw) levels decrease following axon injury to promote increased DLK
levels (Xiong et al., 2010). Although PHR1 negatively regulates DLK in mammals, it is unknown
if PHR1 levels similarly drop in response to axon injury to increase DLK. Alternatively,
mammalian DLK drives a positive-feedback loop in which JNK phosphorylates DLK to protect it
from ubiquitination via PHR1 (Huntwork-Rodriguez et al., 2013).
In addition to increased protein levels, DLK can be activated by several other mechanisms.
In C. elegans, Ca2+ influx directly activates DLK-1, inducing phosphorylation, homodimerization,
and localization to injured axon tips (Yan and Jin, 2012). Mammalian DLK, however, lacks the
Ca2+-binding domain identified in C. elegans DLK-1 (Tedeschi and Bradke, 2013). Additionally,
cAMP-induced protein kinase A (PKA) can phosphorylate DLK in Drosophila and mouse neurons
to stabilize its levels and drive injury signaling (Hao et al., 2016). Interestingly, PKA
phosphorylates DLK on a different site than JNK, suggesting that two independent
phosphorylation-mediated mechanisms drive DLK stability following injury (Hao et al., 2016;
Huntwork-Rodriguez et al., 2013). Additionally, our lab has demonstrated that cytoskeletal
disruption in Drosophila and mouse neurons is sufficient to activate DLK injury signaling. Indeed,
DLK is required for cytoskeletal injury to activate JNK signaling and pharmacological inhibitors
of either actin or microtubules are sufficient to induce the pro-regenerative program in wildtype,
but not DLK KO, DRG neurons (Valakh et al., 2015; Valakh et al., 2013). Recent work has also
demonstrated that palmitoylation targets mammalian DLK to vesicles and is required for DLK
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localization and phosphorylation (Holland et al., 2015). Indeed, palmitoylation is necessary for
DLK to drive injury-induced JNK and cJun phosphorylation (Holland et al., 2015).
DLK in other neuronal contexts
DLK is not only essential for axon regeneration, but also drives neural development and
serves as a global sensor of numerous neuronal insults (Farley and Watkins, 2018; Tedeschi and
Bradke, 2013). In developing Drosophila motor neurons, Wnd regulates synaptic growth, as
overabundance of Wnd, via loss-of-function hiw or direct overexpression, drives synaptic terminal
overgrowth (Collins et al., 2006). Similarly, synaptic defects are observed in C. elegans mutant
for rpm-1 or overexpressing dlk-1 (Nakata et al., 2005).
DLK also drives axon degeneration and apoptosis under many conditions. Following PNS
or CNS axon injury, DLK promotes axon degeneration through JNK (Miller et al., 2009). In CNS
neurons, toxic levels of NMDA also induce apoptosis and degeneration via DLK (Pozniak et al.,
2013). Depriving embryonic DRG neurons of the essential trophic factor, nerve growth factor
(NGF), induces axon degeneration and JNK/cJun-mediated apoptosis (Ghosh et al., 2011). In the
optic nerve, axon crush induces RGC death via DLK/JNK/cJun (Watkins et al., 2013; Welsbie et
al., 2017). Interestingly, a small number of RGCs survive following optic nerve crush and attempt
axon regeneration. Surprisingly, this regeneration, albeit extremely limited, is abolished when
DLK is deleted. Moreover, although DLK drives apoptotic signaling in these CNS neurons, a
number of regeneration-associated genes, such as ATF3, are also induced by DLK (Watkins et al.,
2013). Thus, DLK drives both apoptosis as well as regeneration, but for unknown reasons,
apoptosis remains the default outcome in central neurons. In sum, DLK is responsible for driving
a number of neurodegenerative phenotypes. This has led to intense efforts to target DLK in
neurodegenerative disease. Recently, in mouse models of ALS and Alzheimer’s, Genentech has
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demonstrated that deletion of DLK protects against several disease phenotypes and that potent
DLK inhibitors can reduce motor neuron loss (Le Pichon et al., 2017; Patel et al., 2015). Indeed,
understanding the molecular mechanisms of DLK is vital to develop effective treatments for
neuronal injury and disease.

1.3 Tools to study axon regeneration
There are numerous approaches to identify new genes involved in axon regeneration. In
this section, I will review some commonly used approaches as a primer for understanding how this
dissertation introduces a novel method for selectively identifying components of injury signaling.

1.3.1 Screens
Various high-content screening approaches have successfully broadened our understanding
of the molecular mechanisms of axon regeneration. These unbiased approaches can be separated
into two broad categories: functional screens and ‘omics profiling.
Functional screens
Functional screens assay genes or molecules for a phenotype of interest, such as axon
growth. In vivo screens are commonly performed in model organisms, such as C. elegans or
zebrafish. A genome-wide screen of the C. elegans genes with human orthologs yielded many
novel genes required for axon regeneration post-injury, including signaling molecules,
transcription factors, and cytoskeletal proteins (Nix et al., 2014). Indeed, this screen was the first
to demonstrate DLK is a pro-regenerative kinase essential for axon regeneration (Hammarlund et
al., 2009). Another screen of neuron-specific worm genes, again with human orthologs, identified
a similar set of genes required for axon regeneration following laser axotomy (Chen et al., 2011).
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Given its transparency and neuro-regenerative capacity, the zebrafish is also a convenient model
to screen for axon regeneration genes. The Granato group recently performed a high-content in
vivo screen for pharmacological inhibitors of axon regeneration (Bremer et al., 2017). This study
produced several novel genes implicated in axon regeneration, including topoisomerase 1 and
epidermal growth factor receptor (EGFR).
To identify mammalian genes that promote axon regeneration, groups have performed in
vitro screens with human neuronal cell lines or primary rodent neurons. A kinome-wide RNAi
screen in SH-SY5Y cells identified many MAPKs, tyrosine kinases (TKs), and atypical kinases as
both positive and negative regulators of neurite growth (Loh et al., 2008). Taking an alternative
approach, Li et al. applied 50,400 compounds to ES-derived motor neurons and identified nearly
100 validated hits that, in a dose-dependent manner, promoted neurite outgrowth onto an inhibitory
myelin substrate (Li et al., 2016). Of these, statins were the most potent hits, and worked by
inhibiting prenylation. The authors subsequently demonstrated that prenylation restricts axon
elongation in the CNS and that inhibition of prenylation can enhance RGC axon regeneration in
mice. Many groups have undertaken similar loss-of-function approaches to identify pathways that
prevent axon regrowth in CNS neurons. The Lemmon & Bixby group has performed a number of
high-content pharmacological and genetic loss-of-function screens in rodent hippocampal or
cortical neurons to identify negative regulators of axon regeneration (Al-Ali et al., 2013;
Blackmore et al., 2010; Usher et al., 2010). Nearly all these approaches, however, targeted subsets
of genes or used chemical libraries. Recently, one of the first genome-wide mammalian axon
regeneration screens was published by the Strittmatter group. They knocked down 16,000 genes
in primary mouse cortical neurons and asked which siRNAs improved regeneration following
axotomy (Sekine et al., 2018). Their data defined a new role for Rab27 as a negative regulator of
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axon regeneration. Indeed, Rab27-deficient mice displayed moderately enhanced optic nerve and
spinal cord regeneration following axotomy. In sum, many screens have identified genes that
positively or negatively regulate axon regeneration. Importantly, therapeutically targeting these
genes, however, has only led to subtle improvements of axon regeneration in mammals,
demonstrating the ongoing need to understand how PNS and CNS axons respond to injury.
‘Omics profiling
In addition to observing growth, many groups have sought to identify the mammalian
transcripts and proteins altered by axon injury to better define the injured neuronal state. Several
studies have profiled the genes significantly up- or down-regulated in response to sciatic nerve
injury (Blesch et al., 2012; Chandran et al., 2016; Costigan et al., 2002; Li et al., 2015). In the
hours, days, and weeks following peripheral nerve injury, hundreds of genes within the DRG, are
differentially regulated. Genes associated with cytokines and chemokines, growth factors,
transcription factors, and cytoskeletal components are upregulated (Li et al., 2015). Alternatively,
neurotransmission-related genes are downregulated (Costigan et al., 2002). Phosphoproteomics
has identified that hundreds of proteins, such as signal transduction molecules and transport
proteins, are phosphorylated locally in the axon prior to retrograde transport (Michaelevski et al.,
2010). The focus of these studies is typically the transcription factor network that injury signals
converge upon. Indeed, combining transcriptomics with transcription factor binding site analysis
has produced a list of well-known pro-regenerative transcription factors, which includes ATF3,
cJun, STAT3, Smads, and Cebp (Smith et al., 2011). Unfortunately, overexpressing any one
transcription factor only promotes limited regrowth of CNS axons (Lerch et al., 2014; Smith et al.,
2011), although combinatorial expression shows promise (Chandran et al., 2016). Alternatively,
groups have performed transcriptomics on various CNS neurons to identify downregulated pro15

growth genes. Developing CNS neurons express pro-growth genes only to subsequently
downregulate them postnatally (Moore et al., 2009). Re-expressing these pro-growth genes in mice
promote limited recovery following spinal cord injury (Fink et al., 2017). Similarly, proteomics
revealed that injured RGCs downregulate the pro-regenerative gene c-myc, and exogenous
expression of c-myc can promote limited optic nerve regeneration (Belin et al., 2015).
In sum, these screening efforts have vastly improved our understanding of the global
changes that occur following axon injury and revealed numerous genes involved in regeneration.
These assays are not without their limitations, however. ‘Omics profiling generates exciting lists
of candidate genes, but, without follow-up, is unable to provide functional relevance of the
identified genes. Functional screening overcomes this challenge by using axon growth as the
readout. Nonetheless, a major limitation of current functional screens is that they are unable to
disentangle whether a hit is an injury signal. That is, does the protein function early in the injury
process to induce the regeneration program or does it act later to promote axon elongation and
pathfinding? Thus, while these approaches have provided promising therapeutic targets, they have
not specifically revealed novel components of axon injury signaling. We can, however, interrogate
axon injury signaling in rodents with a functional in vivo assay known as the preconditioning
paradigm. I will review this paradigm below before detailing my approach to combine screening
and preconditioning to identify novel axon injury signals.

1.3.2 The preconditioning phenomenon
Injury to a peripheral axon induces the regeneration program and, after complete activation,
axon regeneration occurs. If the axon undergoes a second injury shortly after the first, the neuron
will immediately regenerate its axon (Pan et al., 2003). The neuron initiates regeneration following
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the second injury more rapidly than after the first because the neuron is preconditioned, or primed,
to respond to the second injury. That is, the regeneration program is functionally active at the time
of the second injury, enabling immediate response. The fascinating nature of this phenomenon
notwithstanding, preconditioning is a vital tool used to assess the state of the regeneration program:
one injury activates the program and a second “testing” injury assays its state. Loss-of-function
experiments using this assay have uncovered many injury-induced proteins required to activate the
regeneration program (Abe et al., 2010; Qiu et al., 2005; Shin et al., 2012).
The discovery of preconditioning dates to the 1960s, when it was thought that waiting 2-3
weeks to repair a human peripheral nerve enhanced patient recovery because neurons had time to
upregulate protein synthesis (Ducker et al., 1969). After trimming back the injured proximal stump
and inserting a biomaterial scaffold, physicians noticed quicker recovery (Ducker et al., 1969). In
1973, Irvine McQuarrie decided to test this hypothesis. He crushed sciatic nerves of rats
(preconditioning lesion) and waited two weeks before transecting them proximal to the first injury
(testing lesion). Preconditioned nerves grew back 21% faster than single-injured nerves
(McQuarrie and Grafstein, 1973). Importantly, because the preconditioning lesion was distal to the
testing lesion, McQuarrie theorized this response was due to changes in the cell body, not the
environment (McQuarrie and Grafstein, 1973).
The preconditioning paradigm is primarily studied in DRG neurons for their
pseudounipolar axon morphology. DRG central axons not only fail to regenerate following injury,
they also do not efficiently regenerate into peripheral nerve grafts (Richardson and Issa, 1984). A
startling discovery was made in 1984 when Richardson and Issa witnessed central DRG axon
regeneration after simultaneously axotomizing both the central and peripheral axons of DRG
neurons (Richardson and Issa, 1984). A preconditioning peripheral lesion enabled regrowth of the
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central axon (Figure 1). DRG central axon regeneration is even greater if the peripheral
preconditioning lesion is given 1 week before the central axon injury (Neumann and Woolf, 1999).
These results provided further evidence that there was an
intrinsic difference in the way CNS and PNS axons
responded to injury and that preconditioning in DRG
neurons could be effectively used to study this process.
Importantly, injury to the central axon does not induce
pro-regenerative signals that upregulate RAGs (Bareyre
et al., 2011; Puttagunta et al., 2014). Similarly, injury to
the PNS axon, not the CNS axon, causes a significant
increase in axonal transport motors and mitochondrial
motility (Mar et al., 2014). Thus, although the DRG
Figure 1 The preconditioning paradigm

central branch remains incapable of responding in mammalian DRG neurons. Adapted

with permission from Elsevier (Hoffman,

positively to axon injury, it can take advantage of pro- 2010)
regenerative signaling induced by a peripheral injury.

Most notably, both McQuarrie et al. and Richardson et al. correctly hypothesized that a
preconditioning injury triggered a global response in the cell body. Thus, the preconditioning
paradigm provides a functional readout of whether the regeneration program is active or not. As
such, it is a valuable tool to specifically identify injury-induced proteins that are required to
activate the regeneration program. This enables disentanglement between upstream genes that
drive injury signaling and downstream genes required for axon extension and pathfinding. In the
last two decades, preconditioning assays have discovered many genes required to induce the axon
regeneration program, including DLK, mTOR, JAK/STAT, and cAMP/PKA (Abe et al., 2010;
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Cafferty et al., 2004; Qiu et al., 2005; Shin et al., 2012). One of the earliest high-profile discoveries
produced by the preconditioning paradigm was that cAMP/PKA signaling can induce the
regenerative state by preconditioning DRGs in the absence of injury (Hannila and Filbin, 2008;
Neumann et al., 2002; Qiu et al., 2002).
The major commonality of these seminal
studies is that they are all performed in vivo, a timeconsuming approach limited to one’s favorite
gene(s) of interest. As a result, identifying new
injury signals has been low-throughput and biased.
To address this challenge, we and others have
recently described an in vitro version of this assay
in which dissection of mouse DRG neurons serves Figure 2 The replating assay, a fully in vitro
preconditioning assay

as the preconditioning lesion (Frey et al., 2015;
Saijilafu et al., 2013; Zou et al., 2009). Twenty-four hours later, the regeneration program is active,
and we administer the testing injury via replating of the neurons. Preconditioned neurons grow
extensive neurites in a short time compared to uninjured neurons (Figure 2). Our lab recently
performed an in-depth characterization of this assay and determined many of the molecular and
functional changes associated with peripheral axon injury are recapitulated in vitro (Frey et al.,
2015). The major advantage that this assay has over the in vivo counterpart is that injury signaling
is induced in culture and so is amenable to loss-of-function pharmacological perturbations. We
can treat neurons with small molecule inhibitors targeting essential axon injury signals to block
induction of the growth program. Importantly, drugs are present only during induction of the
regeneration program, not during axon sprouting or outgrowth. For this dissertation, I miniaturized
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this assay to develop a loss-of-function screening platform to identify small molecules that inhibit
induction of the axon regeneration program. The protein targets of those molecules are novel
components of axon injury signaling. Before presenting my data, I will provide some brief
background on the hit I characterized for this dissertation: heat shock protein 90 (HSP90).

1.4 HSP90
1.4.1 HSP90 biology
HSP90 is a molecular chaperone that is ubiquitously expressed and makes up
approximately 1-2% of total cellular protein (Whitesell and Lindquist, 2005). HSP90 monomers
contain three domains: an ATP-binding domain, a middle domain to bind “clients” (or substrates),
and a dimerization domain. HSP90 chaperone function requires dimerization and ATP hydrolysis.
Mammalian HSP90 exists in several forms, with the predominant forms being HSP90α, which is
induced by heat shock, and the constitutively expressed HSP90β (Schopf et al., 2017). HSP90
function is facilitated by numerous co-chaperones that aid in substrate recognition, conformational
changes, and substrate loading (Schopf et al., 2017). Traditional chaperones such as the HSP60,
HSP70, and HSP100 families drive protein folding, disaggregation, and proteolysis (Saibil, 2013).
HSP90, however, acts after protein synthesis to facilitate maturation, complex assembly,
localization, and ligand binding of signal transduction proteins, including kinases and nuclear
receptors (Taipale et al., 2010). Indeed, HSP90 can interact with over half of the human kinome
(Taipale et al., 2012). This places HSP90 at the center of numerous cellular signaling pathways.
How does HSP90 recognize its clients? It is hypothesized that the numerous HSP90 cochaperones convey client selectively. One of the most well-studied co-chaperones is Cdc37, which
acts as the kinase adapter for HSP90 (Taipale et al., 2012). Nonetheless, within a family of kinases
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with similar structures, HSP90 will chaperone one kinase, but not the others. Studies have failed
to find common motifs that convey HSP90 binding affinity (Taipale et al., 2012). Interestingly,
recent work has demonstrated that HSP90 chaperones unstable kinases (Taipale et al., 2012). Cryoelectron microscopy has revealed that HSP90, in conjunction with Cdc37, can bind and stabilize a
semi-folded kinase before mediating the final folding (Verba et al., 2016). It is thought that Cdc37
scans kinases, binds to those that are unstable, and creates a complex that has high affinity towards
HSP90 (Keramisanou et al., 2016). Collectively, these data have led to the hypothesis that HSP90
preferentially chaperones semi-folded, dynamic kinases to facilitate the final conformational
changes that enable signaling (Verba and Agard, 2017).
A HSP90-client relationship is characterized by two key features: 1) the two proteins
physically interact, and 2) the client protein is degraded upon loss of chaperone function (Whitesell
and Lindquist, 2005). For example, the MAP3K, MLK3, is a known client of HSP90. HSP90
immunoprecipitates with MLK3 and treatment of cells with HSP90 inhibitor depletes MLK3
protein within 10 hours (Zhang et al., 2004). Commonly, the client protein is ubiquitinated and
degraded via the proteasome (Wang et al., 2008). HSP90 is typically studied in the context of
cancer, as its chaperone activity stabilizes numerous oncogenes (Whitesell and Lindquist, 2005).
Nonetheless, there are a few established roles for HSP90 in neurons.

1.4.2 HSP90 in neurons
Knowledge of HSP90 function in neurons is somewhat limited. The main areas of research
focus on the mechanisms of HSP90 in neurodegeneration. Similar to HSP90’s role in cancer,
HSP90 chaperone activity stabilizes toxic protein aggregates to enable sustained accumulation in
many neuropathologies, including Huntington’s, Parkinson’s, and Alzheimer’s diseases (Lackie et
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al., 2017; Luo et al., 2010). For example, HSP90 chaperones mutant, but not wildtype, tau in mouse
models of Alzheimer’s (Luo et al., 2007). In this model, the p35/CDK5 complex drives tau
hyperphosphorylation and is dependent on HSP90 activity (Luo et al., 2007). Thus, HSP90 not
only stabilizes mutant protein aggregates, but may also directly influence the aberrant signaling
that creates such aggregates. Indeed, mutant leucine-rich repeat kinase 2 (LRRK2), a critical
genetic driver of familial and sporadic Parkinson’s disease, is also dependent on functional HSP90
(Wang et al., 2008).
HSP90 also has a few neuronal functions outside of disease. In developing hippocampal
neurons, HSP90 chaperones glycogen synthase kinase 3 (GSK) and Akt to drive neuronal
polarization and axon specification (Benitez et al., 2014). Also during development, C. elegans
HSP90 maintains the axon guidance protein SAX-3 (Robo in mammals) to modulate axon
pathfinding (Wang et al., 2013). In mature neurons, HSP90 is required for synaptic transmission
in hippocampal neurons (Gerges et al., 2004). Thus, HSP90 is clearly required for several neuronal
functions, however the amount of data is limited, particularly in comparison to other well-studied
paradigms such as cancer. Importantly, there is no data describing a role for HSP90 in axon injury.

1.5 Summary
This introduction has summarized the current knowledge of axon regeneration and the
molecular mechanisms by which peripheral neurons trigger a pro-regenerative state to facilitate
efficient axonal repair. While many injury signals are extensively studied, there exists no largescale unbiased approach to functionally identify novel axon injury signals. My dissertation aims
to address this gap of knowledge. In the following chapter, I describe a high-content functional
screen that selectively probes for components of axon injury signaling. I uncover a novel role for
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HSP90 in axon injury signaling and describe a possible mechanism by which HSP90 facilitates
this process: by chaperoning the essential neuronal kinase, DLK. As discussed, DLK is at the
center of neuronal development, injury, and disease. Thus, my findings are two-fold: 1) HSP90 is
a newly identified component of axon injury signaling, and 2) HSP90 chaperone activity is a novel
mechanism of DLK regulation.

23

References
Abe, N., Almenar-Queralt, A., Lillo, C., Shen, Z., Lozach, J., Briggs, S.P., Williams, D.S.,
Goldstein, L.S., and Cavalli, V. (2009). Sunday driver interacts with two distinct classes of axonal
organelles. J Biol Chem 284, 34628-34639.
Abe, N., Borson, S.H., Gambello, M.J., Wang, F., and Cavalli, V. (2010). Mammalian target of
rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J
Biol Chem 285, 28034-28043.
Abe, N., and Cavalli, V. (2008). Nerve injury signaling. Curr Opin Neurobiol 18, 276-283.
Al-Ali, H., Schürer, S.C., Lemmon, V.P., and Bixby, J.L. (2013). Chemical interrogation of the
neuronal kinome using a primary cell-based screening assay. ACS Chem Biol 8, 1027-1036.
Babetto, E., Beirowski, B., Russler, E.V., Milbrandt, J., and DiAntonio, A. (2013). The Phr1
ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep 3, 1422-1429.
Bareyre, F.M., Garzorz, N., Lang, C., Misgeld, T., Büning, H., and Kerschensteiner, M. (2011). In
vivo imaging reveals a phase-specific role of STAT3 during central and peripheral nervous system
axon regeneration. Proc Natl Acad Sci U S A 108, 6282-6287.
Belin, S., Nawabi, H., Wang, C., Tang, S., Latremoliere, A., Warren, P., Schorle, H., Uncu, C.,
Woolf, C.J., He, Z., et al. (2015). Injury-induced decline of intrinsic regenerative ability revealed
by quantitative proteomics. Neuron 86, 1000-1014.
Benitez, M.J., Sanchez-Ponce, D., Garrido, J.J., and Wandosell, F. (2014). Hsp90 activity is
necessary to acquire a proper neuronal polarization. Biochim Biophys Acta 1843, 245-252.
Blackmore, M.G., Moore, D.L., Smith, R.P., Goldberg, J.L., Bixby, J.L., and Lemmon, V.P.
(2010). High content screening of cortical neurons identifies novel regulators of axon growth. Mol
Cell Neurosci 44, 43-54.
Blesch, A., Lu, P., Tsukada, S., Alto, L.T., Roet, K., Coppola, G., Geschwind, D., and Tuszynski,
M.H. (2012). Conditioning lesions before or after spinal cord injury recruit broad genetic
mechanisms that sustain axonal regeneration: superiority to camp-mediated effects. Exp Neurol
235, 162-173.
Brace, E.J., Wu, C., Valakh, V., and DiAntonio, A. (2014). SkpA restrains synaptic terminal
growth during development and promotes axonal degeneration following injury. J Neurosci 34,
8398-8410.
Bradke, F., Fawcett, J., and Spira, M. (2012). Assembly of a new growth cone after axotomy: the
precursor to axon regeneration. Nat Rev Neurosci 13, 183-193.
Bremer, J., Skinner, J., and Granato, M. (2017). A small molecule screen identifies in vivo
modulators of peripheral nerve regeneration in zebrafish. PLoS One 12.
24

Cafferty, W.B., Gardiner, N.J., Das, P., Qiu, J., McMahon, S.B., and Thompson, S.W. (2004).
Conditioning injury-induced spinal axon regeneration fails in interleukin-6 knock-out mice. J
Neurosci 24, 4432-4443.
Cavalli, V., Kujala, P., Klumperman, J., and Goldstein, L.S. (2005). Sunday Driver links axonal
transport to damage signaling. J Cell Biol 168, 775-787.
Chandran, V., Coppola, G., Nawabi, H., Omura, T., Versano, R., Huebner, E.A., Zhang, A.,
Costigan, M., Yekkirala, A., Barrett, L., et al. (2016). A Systems-Level Analysis of the Peripheral
Nerve Intrinsic Axonal Growth Program. Neuron 89, 956-970.
Chen, L., Wang, Z., Ghosh-Roy, A., Hubert, T., Yan, D., O'Rourke, S., Bowerman, B., Wu, Z.,
Jin, Y., and Chisholm, A.D. (2011). Axon regeneration pathways identified by systematic genetic
screening in C. elegans. Neuron 71, 1043-1057.
Cho, Y., and Cavalli, V. (2012). HDAC5 is a novel injury-regulated tubulin deacetylase controlling
axon regeneration. The EMBO journal 31, 3063-3078.
Cho, Y., Shin, J.E., Ewan, E.E., Oh, Y.M., Pita-Thomas, W., and Cavalli, V. (2015). Activating
Injury-Responsive Genes with Hypoxia Enhances Axon Regeneration through Neuronal HIF-1α.
Neuron 88, 720-734.
Cho, Y., Sloutsky, R., Naegle, K.M., and Cavalli, V. (2013). Injury-induced HDAC5 nuclear
export is essential for axon regeneration. Cell 155, 894-908.
Christie, K., and Zochodne, D. (2013). Peripheral axon regrowth: new molecular approaches.
Neuroscience 240, 310-324.
Collins, C.A., Wairkar, Y.P., Johnson, S.L., and DiAntonio, A. (2006). Highwire restrains synaptic
growth by attenuating a MAP kinase signal. Neuron 51, 57-69.
Costigan, M., Befort, K., Karchewski, L., Griffin, R.S., D'Urso, D., Allchorne, A., Sitarski, J.,
Mannion, J.W., Pratt, R.E., and Woolf, C.J. (2002). Replicate high-density rat genome
oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after
peripheral nerve injury. BMC Neurosci 3, 16.
Davis, R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252.
Ducker, T., Kempe, L., and Hayes, G. (1969). The metabolic background for peripheral nerve
surgery. Journal of neurosurgery 30, 270-280.
Fan, G., Merritt, S.E., Kortenjann, M., Shaw, P.E., and Holzman, L.B. (1996). Dual leucine zipperbearing kinase (DLK) activates p46SAPK and p38mapk but not ERK2. J Biol Chem 271, 2478824793.
Farley, M.M., and Watkins, T.A. (2018). Intrinsic Neuronal Stress Response Pathways in Injury
and Disease. Annu Rev Pathol 13, 93-116.
25

Finelli, M.J., Wong, J.K., and Zou, H. (2013). Epigenetic regulation of sensory axon regeneration
after spinal cord injury. J Neurosci 33, 19664-19676.
Fink, K.L., López-Giráldez, F., Kim, I.-J.J., Strittmatter, S.M., and Cafferty, W.B.J.B.J. (2017).
Identification of Intrinsic Axon Growth Modulators for Intact CNS Neurons after Injury. Cell Rep
18, 2687-2701.
Frey, E., Valakh, V., Karney-Grobe, S., Shi, Y., Milbrandt, J., and DiAntonio, A. (2015). An in
vitro assay to study induction of the regenerative state in sensory neurons. Exp Neurol 263, 350363.
Gerges, N.Z., Tran, I.C., Backos, D.S., Harrell, J.M., Chinkers, M., Pratt, W.B., and Esteban,
J.A.A. (2004). Independent functions of hsp90 in neurotransmitter release and in the continuous
synaptic cycling of AMPA receptors. J Neurosci 24, 4758-4766.
Ghosh-Roy, A., Wu, Z., Goncharov, A., Jin, Y., and Chisholm, A.D. (2010). Calcium and cyclic
AMP promote axonal regeneration in Caenorhabditis elegans and require DLK-1 kinase. J
Neurosci 30, 3175-3183.
Ghosh, A.S., Wang, B., Pozniak, C.D., Chen, M., Watts, R.J., and Lewcock, J.W. (2011). DLK
induces developmental neuronal degeneration via selective regulation of proapoptotic JNK
activity. J Cell Biol 194, 751-764.
Hammarlund, M., Nix, P., Hauth, L., Jorgensen, E.M., and Bastiani, M. (2009). Axon regeneration
requires a conserved MAP kinase pathway. Science 323, 802-806.
Hannila, S.S., and Filbin, M.T. (2008). The role of cyclic AMP signaling in promoting axonal
regeneration after spinal cord injury. Exp Neurol 209, 321-332.
Hanz, S., Perlson, E., Willis, D., Zheng, J.-Q.Q., Massarwa, R.a., Huerta, J.J., Koltzenburg, M.,
Kohler, M., van-Minnen, J., Twiss, J.L., et al. (2003). Axoplasmic importins enable retrograde
injury signaling in lesioned nerve. Neuron 40, 1095-1104.
Hao, Y., Frey, E., Yoon, C., Wong, H., Nestorovski, D., Holzman, L.B., Giger, R.J., DiAntonio,
A., and Collins, C. (2016). An evolutionarily conserved mechanism for cAMP elicited axonal
regeneration involves direct activation of the dual leucine zipper kinase DLK. eLife 5.
He, Z., and Jin, Y. (2016). Intrinsic Control of Axon Regeneration. Neuron 90, 437-451.
Hoffman, P.N. (2010). A conditioning lesion induces changes in gene expression and axonal
transport that enhance regeneration by increasing the intrinsic growth state of axons. Exp Neurol
223, 11-18.
Holland, S.M., Collura, K.M., Ketschek, A., Noma, K., Ferguson, T.A., Jin, Y., Gallo, G., and
Thomas, G.M. (2015). Palmitoylation controls DLK localization, interactions and activity to
ensure effective axonal injury signaling. Proc Natl Acad Sci U S A.

26

Holzman, L.B., Merritt, S.E., and Fan, G. (1994). Identification, molecular cloning, and
characterization of dual leucine zipper bearing kinase. A novel serine/threonine protein kinase that
defines a second subfamily of mixed lineage kinases. J Biol Chem 269, 30808-30817.
Huntwork-Rodriguez, S., Wang, B., Watkins, T., Ghosh, A.S., Pozniak, C.D., Bustos, D., Newton,
K., Kirkpatrick, D.S., and Lewcock, J.W. (2013). JNK-mediated phosphorylation of DLK
suppresses its ubiquitination to promote neuronal apoptosis. J Cell Biol 202, 747-763.
Keramisanou, D., Aboalroub, A., Zhang, Z., Liu, W., Marshall, D., Diviney, A., Larsen, R.W.,
Landgraf, R., and Gelis, I. (2016). Molecular Mechanism of Protein Kinase Recognition and
Sorting by the Hsp90 Kinome-Specific Cochaperone Cdc37. Mol Cell 62, 260-271.
Lackie, R.E., Maciejewski, A., Ostapchenko, V.G., Marques-Lopes, J., Choy, W.-Y.Y.,
Duennwald, M.L., Prado, V.F., and Prado, M.A.M.A.M. (2017). The Hsp70/Hsp90 Chaperone
Machinery in Neurodegenerative Diseases. Front Neurosci 11, 254.
Le Pichon, C.E., Meilandt, W.J., Dominguez, S., Solanoy, H., Lin, H., Ngu, H., Gogineni, A.,
Sengupta Ghosh, A., Jiang, Z., Lee, S.-H.H., et al. (2017). Loss of dual leucine zipper kinase
signaling is protective in animal models of neurodegenerative disease. Sci Transl Med 9.
Leclere, P., Norman, E., Groutsi, F., Coffin, R., Mayer, U., Pizzey, J., and Tonge, D. (2007).
Impaired axonal regeneration by isolectin B4-binding dorsal root ganglion neurons in vitro. J
Neurosci 27, 1190-1199.
Lee, N., Neitzel, K.L., Devlin, B.K., and MacLennan, A.J. (2004). STAT3 phosphorylation in
injured axons before sensory and motor neuron nuclei: potential role for STAT3 as a retrograde
signaling transcription factor. The Journal of comparative neurology 474, 535-545.
Lerch, J.K., Martínez-Ondaro, Y.R., Bixby, J.L., and Lemmon, V.P. (2014). cJun promotes CNS
axon growth. Mol Cell Neurosci 59, 97-105.
Li, H., Kuwajima, T., Oakley, D., Nikulina, E., Hou, J., Yang, W.S., Lowry, E.R., Lamas, N.J.,
Amoroso, M.W., Croft, G.F., et al. (2016). Protein Prenylation Constitutes an Endogenous Brake
on Axonal Growth. Cell Rep 16, 545-558.
Li, S., Xue, C., Yuan, Y., Zhang, R., Wang, Y., Wang, Y., Yu, B., Liu, J., Ding, F., Yang, Y., et
al. (2015). The transcriptional landscape of dorsal root ganglia after sciatic nerve transection. Sci
Rep 5, 16888.
Lindwall, C., Dahlin, L., Lundborg, G., and Kanje, M. (2004). Inhibition of c-Jun phosphorylation
reduces axonal outgrowth of adult rat nodose ganglia and dorsal root ganglia sensory neurons. Mol
Cell Neurosci 27, 267-279.
Lindwall, C., and Kanje, M. (2005). Retrograde axonal transport of JNK signaling molecules
influence injury induced nuclear changes in p-c-Jun and ATF3 in adult rat sensory neurons. Mol
Cell Neurosci 29, 269-282.

27

Liu, K., Lu, Y., Lee, J.K., Samara, R., Willenberg, R., Sears-Kraxberger, I., Tedeschi, A., Park,
K.K., Jin, D., Cai, B., et al. (2010). PTEN deletion enhances the regenerative ability of adult
corticospinal neurons. Nat Neurosci 13, 1075-1081.
Liu, K., Tedeschi, A., Park, K., and He, Z. (2011). Neuronal intrinsic mechanisms of axon
regeneration. Annu Rev Neurosci 34, 131-152.
Loh, S.H., Francescut, L., Lingor, P., Bähr, M., and Nicotera, P. (2008). Identification of new
kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA
interference screen. Cell Death Differ 15, 283-298.
Luo, W., Dou, F., Rodina, A., Chip, S., Kim, J., Zhao, Q., Moulick, K., Aguirre, J., Wu, N.,
Greengard, P., et al. (2007). Roles of heat-shock protein 90 in maintaining and facilitating the
neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 104, 9511-9516.
Luo, W., Sun, W., Taldone, T., Rodina, A., and Chiosis, G. (2010). Heat shock protein 90 in
neurodegenerative diseases. Mol Neurodegener 5, 24.
Mahar, M., and Cavalli, V. (2018). Intrinsic mechanisms of neuronal axon regeneration. Nature
reviews Neuroscience.
Mandolesi, G., Madeddu, F., Bozzi, Y., Maffei, L., and Ratto, G.M. (2004). Acute physiological
response of mammalian central neurons to axotomy: ionic regulation and electrical activity.
FASEB journal : official publication of the Federation of American Societies for Experimental
Biology 18, 1934-1936.
Mar, F.M., Simões, A.R., Leite, S., Morgado, M.M., Santos, T.E., Rodrigo, I.S., Teixeira, C.A.,
Misgeld, T., and Sousa, M.M. (2014). CNS axons globally increase axonal transport after
peripheral conditioning. J Neurosci 34, 5965-5970.
Mason, M., Lieberman, A., Grenningloh, G., and Anderson, P. (2002). Transcriptional
upregulation of SCG10 and CAP-23 is correlated with regeneration of the axons of peripheral and
central neurons in vivo. Mol Cell Neurosci 20, 595-615.
Mata, M., Merritt, S.E., Fan, G., Yu, G.G., and Holzman, L.B. (1996). Characterization of dual
leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose
phosphorylation state is regulated by membrane depolarization via calcineurin. J Biol Chem 271,
16888-16896.
McQuarrie, I., and Grafstein, B. (1973). Axon outgrowth enhanced by a previous nerve injury.
Archives of neurology 29, 53-55.
Michaelevski, I., Segal-Ruder, Y., Rozenbaum, M., Medzihradszky, K.F., Shalem, O., Coppola,
G., Horn-Saban, S., Ben-Yaakov, K., Dagan, S.Y., Rishal, I., et al. (2010). Signaling to
transcription networks in the neuronal retrograde injury response. Sci Signal 3.

28

Miller, B.R., Press, C., Daniels, R.W., Sasaki, Y., Milbrandt, J., and DiAntonio, A. (2009). A dual
leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat
Neurosci 12, 387-389.
Misgeld, T., and Schwarz, T.L. (2017). Mitostasis in Neurons: Maintaining Mitochondria in an
Extended Cellular Architecture. Neuron 96, 651-666.
Moore, D.L., Blackmore, M.G., Hu, Y., Kaestner, K.H., Bixby, J.L., Lemmon, V.P., and Goldberg,
J.L. (2009). KLF family members regulate intrinsic axon regeneration ability. Science 326, 298301.
Moore, D.L., and Goldberg, J.L. (2011). Multiple transcription factor families regulate axon
growth and regeneration. Dev Neurobiol 71, 1186-1211.
Nakata, K., Abrams, B., Grill, B., Goncharov, A., and Cell, H.-X. (2005). Regulation of a DLK-1
and p38 MAP kinase pathway by the ubiquitin ligase RPM-1 is required for presynaptic
development. Cell 120, 407-420.
Neumann, S., Bradke, F., Tessier-Lavigne, M., and Basbaum, A.I. (2002). Regeneration of sensory
axons within the injured spinal cord induced by intraganglionic cAMP elevation. Neuron 34, 885893.
Neumann, S., and Woolf, C.J. (1999). Regeneration of dorsal column fibers into and beyond the
lesion site following adult spinal cord injury. Neuron 23, 83-91.
Nihalani, D., Merritt, S., and Holzman, L.B. (2000). Identification of structural and functional
domains in mixed lineage kinase dual leucine zipper-bearing kinase required for complex
formation and stress-activated protein kinase activation. J Biol Chem 275, 7273-7279.
Nix, P., Hammarlund, M., Hauth, L., Lachnit, M., Jorgensen, E.M., and Bastiani, M. (2014). Axon
regeneration genes identified by RNAi screening in C. elegans. J Neurosci 34, 629-645.
Nix, P., Hisamoto, N., Matsumoto, K., and Bastiani, M. (2011). Axon regeneration requires
coordinate activation of p38 and JNK MAPK pathways. Proc Natl Acad Sci U S A 108, 1073810743.
Pan, Y.A., Misgeld, T., Lichtman, J.W., and Sanes, J.R. (2003). Effects of neurotoxic and
neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J
Neurosci 23, 11479-11488.
Park, K.K., Liu, K., Hu, Y., Kanter, J.L., and He, Z. (2010). PTEN/mTOR and axon regeneration.
Exp Neurol 223, 45-50.
Park, K.K., Liu, K., Hu, Y., Smith, P.D., Wang, C., Cai, B., Xu, B., Connolly, L., Kramvis, I.,
Sahin, M., et al. (2008). Promoting axon regeneration in the adult CNS by modulation of the
PTEN/mTOR pathway. Science 322, 963-966.

29

Patel, S., Cohen, F., Dean, B.J., De La Torre, K., Deshmukh, G., Estrada, A.A., Ghosh, A.S.,
Gibbons, P., Gustafson, A., Huestis, M.P., et al. (2015). Discovery of dual leucine zipper kinase
(DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem 58, 401418.
Perlson, E., Hanz, S., Ben-Yaakov, K., Segal-Ruder, Y., Seger, R., and Fainzilber, M. (2005).
Vimentin-dependent spatial translocation of an activated MAP kinase in injured nerve. Neuron 45,
715-726.
Pozniak, C.D., Sengupta Ghosh, A., Gogineni, A., Hanson, J.E., Lee, S.-H.H., Larson, J.L.,
Solanoy, H., Bustos, D., Li, H., Ngu, H., et al. (2013). Dual leucine zipper kinase is required for
excitotoxicity-induced neuronal degeneration. J Exp Med 210, 2553-2567.
Puttagunta, R., Tedeschi, A., Sória, M.G., Hervera, A., Lindner, R., Rathore, K.I., Gaub, P., Joshi,
Y., Nguyen, T., Schmandke, A., et al. (2014). PCAF-dependent epigenetic changes promote
axonal regeneration in the central nervous system. Nat Commun 5, 3527.
Qin, S., Zou, Y., and Zhang, C.-L.L. (2013). Cross-talk between KLF4 and STAT3 regulates axon
regeneration. Nat Commun 4, 2633.
Qiu, J., Cafferty, W.B., McMahon, S.B., and Thompson, S.W. (2005). Conditioning injuryinduced spinal axon regeneration requires signal transducer and activator of transcription 3
activation. J Neurosci 25, 1645-1653.
Qiu, J., Cai, D., Dai, H., McAtee, M., Hoffman, P.N., Bregman, B.S., and Filbin, M.T. (2002).
Spinal axon regeneration induced by elevation of cyclic AMP. Neuron 34, 895-903.
Raivich, G., Bohatschek, M., Da Costa, C., Iwata, O., Galiano, M., Hristova, M., Nateri, A.S.,
Makwana, M., Riera-Sans, L., Wolfer, D.P., et al. (2004). The AP-1 transcription factor c-Jun is
required for efficient axonal regeneration. Neuron 43, 57-67.
Ramon y Cajal, S. (1928). Degeneration and regeneration of the nervous system. London: Oxford
University Press.
Richardson, P., and Issa, V. (1984). Peripheral injury enhances central regeneration of primary
sensory neurones. Nature 309, 791-793.
Rishal, I., and Fainzilber, M. (2010). Retrograde signaling in axonal regeneration. Exp Neurol 223,
5-10.
Rishal, I., and Fainzilber, M. (2014). Axon-soma communication in neuronal injury. Nat Rev
Neurosci 15, 32-42.
Saibil, H. (2013). Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev
Mol Cell Biol 14, 630-642.

30

Saijilafu, Hur, E.-M.M., Liu, C.-M.M., Jiao, Z., Xu, W.-L.L., and Zhou, F.-Q.Q. (2013). PI3KGSK3 signalling regulates mammalian axon regeneration by inducing the expression of Smad1.
Nat Commun 4, 2690.
Schopf, F.H., Biebl, M.M., and Buchner, J. (2017). The HSP90 chaperone machinery. Nat Rev
Mol Cell Biol 18, 345-360.
Seijffers, R., Allchorne, A.J., and Woolf, C.J. (2006). The transcription factor ATF-3 promotes
neurite outgrowth. Mol Cell Neurosci 32, 143-154.
Seijffers, R., Mills, C.D., and Woolf, C.J. (2007). ATF3 increases the intrinsic growth state of
DRG neurons to enhance peripheral nerve regeneration. J Neurosci 27, 7911-7920.
Sekine, Y., Lin-Moore, A., Chenette, D.M., Wang, X., Jiang, Z., Cafferty, W.B., Hammarlund,
M., and Strittmatter, S.M. (2018). Functional Genome-wide Screen Identifies Pathways
Restricting Central Nervous System Axonal Regeneration. Cell Rep 23, 415-428.
Shin, J.E., and Cho, Y. (2017). Epigenetic Regulation of Axon Regeneration after Neural Injury.
Mol Cells 40, 10-16.
Shin, J.E., Cho, Y., Beirowski, B., Milbrandt, J., Cavalli, V., and DiAntonio, A. (2012). Dual
leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron
74, 1015-1022.
Smith, D., and Skene, J. (1997). A transcription-dependent switch controls competence of adult
neurons for distinct modes of axon growth. J Neurosci 17, 646-658.
Smith, P.D., Sun, F., Park, K.K., Cai, B., Wang, C., Kuwako, K., Martinez-Carrasco, I., Connolly,
L., and He, Z. (2009). SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron 64, 617623.
Smith, R.P., Lerch-Haner, J.K., Pardinas, J.R., Buchser, W.J., Bixby, J.L., and Lemmon, V.P.
(2011). Transcriptional profiling of intrinsic PNS factors in the postnatal mouse. Mol Cell
Neurosci 46, 32-44.
Sun, F., Park, K.K., Belin, S., Wang, D., Lu, T., Chen, G., Zhang, K., Yeung, C., Feng, G.,
Yankner, B.A., et al. (2011). Sustained axon regeneration induced by co-deletion of PTEN and
SOCS3. Nature 480, 372-375.
Taipale, M., Jarosz, D.F., and Lindquist, S. (2010). HSP90 at the hub of protein homeostasis:
emerging mechanistic insights. Nat Rev Mol Cell Biol 11, 515-528.
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K.D., Karras, G.I., and Lindquist,
S. (2012). Quantitative analysis of HSP90-client interactions reveals principles of substrate
recognition. Cell 150, 987-1001.
Tedeschi, A. (2011). Tuning the orchestra: transcriptional pathways controlling axon regeneration.
Front Mol Neurosci 4, 60.
31

Tedeschi, A., and Bradke, F. (2013). The DLK signalling pathway--a double-edged sword in
neural development and regeneration. EMBO reports 14, 605-614.
Usher, L.C., Johnstone, A., Ertürk, A., Hu, Y., Strikis, D., Wanner, I.B., Moorman, S., Lee, J.W.W., Min, J., Ha, H.-H.H., et al. (2010). A chemical screen identifies novel compounds that
overcome glial-mediated inhibition of neuronal regeneration. J Neurosci 30, 4693-4706.
Valakh, V., Frey, E., Babetto, E., Walker, L.J., and DiAntonio, A. (2015). Cytoskeletal disruption
activates the DLK/JNK pathway, which promotes axonal regeneration and mimics a
preconditioning injury. Neurobiol Dis 77, 13-25.
Valakh, V., Walker, L.J., Skeath, J.B., and DiAntonio, A. (2013). Loss of the spectraplakin short
stop activates the DLK injury response pathway in Drosophila. J Neurosci 33, 17863-17873.
van Kesteren, R., Mason, M., Macgillavry, H., Smit, A., and Verhaagen, J. (2011). A gene network
perspective on axonal regeneration. Front Mol Neurosci 4, 46.
Verba, K.A., and Agard, D.A. (2017). How Hsp90 and Cdc37 Lubricate Kinase Molecular
Switches. Trends Biochem Sci 42, 799-811.
Verba, K.A., Wang, R.R., Arakawa, A., Liu, Y., Shirouzu, M., Yokoyama, S., and Agard, D.A.
(2016). Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an
unfolded kinase. Science 352, 1542-1547.
Wang, L., Xie, C., Greggio, E., Parisiadou, L., Shim, H., Sun, L., Chandran, J., Lin, X., Lai, C.,
Yang, W.-J.J., et al. (2008). The chaperone activity of heat shock protein 90 is critical for
maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28, 3384-3391.
Wang, Z., Hou, Y., Guo, X., van der Voet, M., Boxem, M., Dixon, J.E., Chisholm, A.D., and Jin,
Y. (2013). The EBAX-type Cullin-RING E3 ligase and Hsp90 guard the protein quality of the
SAX-3/Robo receptor in developing neurons. Neuron 79, 903-916.
Watkins, T.A., Wang, B., Huntwork-Rodriguez, S., Yang, J., Jiang, Z., Eastham-Anderson, J.,
Modrusan, Z., Kaminker, J.S., Tessier-Lavigne, M., and Lewcock, J.W. (2013). DLK initiates a
transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc
Natl Acad Sci U S A 110, 4039-4044.
Welsbie, D.S., Mitchell, K.L., Jaskula-Ranga, V., Sluch, V.M., Yang, Z., Kim, J., Buehler, E.,
Patel, A., Martin, S.E., Zhang, P.-W.W., et al. (2017). Enhanced Functional Genomic Screening
Identifies Novel Mediators of Dual Leucine Zipper Kinase-Dependent Injury Signaling in
Neurons. Neuron 94, 1142-1154000000.
Weng, Y.-L.L., An, R., Cassin, J., Joseph, J., Mi, R., Wang, C., Zhong, C., Jin, S.-G.G., Pfeifer,
G.P., Bellacosa, A., et al. (2017). An Intrinsic Epigenetic Barrier for Functional Axon
Regeneration. Neuron 94, 337-346000000.
Whitesell, L., and Lindquist, S.L. (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer
5, 761-772.
32

Xiong, X., Wang, X., Ewanek, R., Bhat, P., Diantonio, A., and Collins, C.A. (2010). Protein
turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. J Cell Biol
191, 211-223.
Yan, D., and Jin, Y. (2012). Regulation of DLK-1 kinase activity by calcium-mediated dissociation
from an inhibitory isoform. Neuron 76, 534-548.
Ying, Z., Misra, V., and Verge, V.M. (2014). Sensing nerve injury at the axonal ER: Activated
Luman/CREB3 serves as a novel axonally synthesized retrograde regeneration signal. Proc Natl
Acad Sci U S A.
Zhang, H., Wu, W., Du, Y., Santos, S.J., Conrad, S.E., Watson, J.T., Grammatikakis, N., and
Gallo, K.A. (2004). Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling. J
Biol Chem 279, 19457-19463.
Zou, H., Ho, C., Wong, K., and Tessier-Lavigne, M. (2009). Axotomy-induced Smad1 activation
promotes axonal growth in adult sensory neurons. J Neurosci 29, 7116-7123.

33

Chapter 2: HSP90 is a chaperone for DLK and
is required for axon injury signaling

This chapter was submitted to the Proceedings of the National Academy of Sciences as:
Karney-Grobe S, Russo A, Frey E, Milbrandt J, DiAntonio A. (2018) HSP90 is a chaperone for
DLK and is required for axon injury signaling. Proc. Natl. Acad. Sci. USA. In revision.
Author contributions: S.K.G., A.R., J.M., and A.D. designed the research. S.K.G., A.R., and E.F.
performed the research. S.K.G. and A.R. analyzed the data. S.K.G. and A.D. wrote the paper.

34

2.1 Abstract
Peripheral nerve injury induces a robust pro-regenerative program that drives axon
regeneration. While many regeneration-associated genes are known, the mechanisms by which
injury activates them are less well understood. To identify such mechanisms, we performed a lossof-function pharmacological screen in cultured adult mouse sensory neurons for proteins required
to activate this program. Well-characterized inhibitors were present as injury signaling was
induced, but were removed before axon outgrowth to identify molecules that block induction of
the program. Of 480 compounds, 35 prevented injury-induced neurite regrowth. The top hits were
inhibitors to heat shock protein 90 (HSP90), a chaperone with no known role in axon injury. HSP90
inhibition blocks injury-induced activation of the pro-regenerative transcription factor cJun and
several regeneration-associated genes. These phenotypes mimic loss of the pro-regenerative
MAP3K, dual leucine zipper kinase (DLK), a critical neuronal stress sensor that drives axon
degeneration, axon regeneration, and cell death. HSP90 is an atypical chaperone that promotes the
stability of signaling molecules. HSP90 and DLK demonstrate two hallmarks of HSP90-client
relationships: 1) HSP90 binds DLK and 2) HSP90 inhibition leads to rapid degradation of existing
DLK protein. Moreover, HSP90 is required for DLK stability in vivo, where HSP90 inhibitor
reduces DLK protein in the sciatic nerve. This phenomenon is evolutionarily conserved in
Drosophila. Genetic knockdown of Drosophila HSP90, Hsp83, decreases levels of Drosophila
DLK, Wallenda, and blocks Wallenda-dependent synaptic terminal overgrowth and injury
signaling. Our findings support the hypothesis that HSP90 chaperones DLK and is required for
DLK functions, including pro-regenerative axon injury signaling.
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2.2 Significance statement
Defining mechanisms of axon injury signaling is critical to understand axon regeneration.
This knowledge can be used to develop strategies of axonal repair. Identification of such injury
signals has been limited by traditional in vivo assays of pro-regenerative injury signaling. Here,
we describe an in vitro screening platform that specifically identifies pro-regenerative axon injury
signals in mouse neurons. We show that HSP90 is required for injury signaling and detail a
mechanism by which HSP90 chaperones the essential pro-regenerative kinase, dual leucine zipper
kinase (DLK). Thus, this work also describes a novel mechanism by which HSP90 regulates DLK,
a critical neuronal stress sensor that drives axon regeneration, degeneration, and neurological
disease.

2.3 Introduction
Axon injury occurs in response to trauma, metabolic and toxic insults, and
neurodegenerative and genetic diseases. Understanding axonal injury response pathways may lead
to strategies for axonal repair. While mammalian central axon regeneration is stunted by a nonpermissive environment and low intrinsic growth capacity (Bradke et al., 2012; Farley and
Watkins, 2018), peripheral axons can undergo robust regeneration and thus provide an attractive
system to study pro-regenerative signaling. Peripheral nerve injury activates cytoskeletal
remodeling that transforms the injured axon tip into a growth cone (Bradke et al., 2012).
Concurrently, local signaling molecules detect the injury and drive retrograde signals to the
nucleus to induce expression of regeneration-associated genes (Rishal and Fainzilber, 2014). This
transcriptional program transforms the neuron into a pro-regenerative state to enable efficient axon
regeneration (Abe and Cavalli, 2008; Smith and Skene, 1997).
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Dual leucine zipper kinase (DLK) is an essential axon injury sensor and MAP triple kinase
that activates the c-Jun N-terminal kinase (JNK) and p38 families (Klinedinst et al., 2013; Miller
et al., 2009; Shin et al., 2012a). DLK promotes retrograde transport of injury signals and is required
for axon regeneration in mice, Drosophila, and C. elegans (Hammarlund et al., 2009; Shin et al.,
2014; Watkins et al., 2013; Xiong et al., 2010). Along with DLK, a handful of other kinases,
transcription factors, and histone modifiers drive regenerative axon signaling, and additional
factors are likely yet undiscovered (Michaelevski et al., 2010; Shin and Cho, 2017; Tedeschi and
Bradke, 2013). We sought to identify new components of the axon injury response, either novel
pathways or new regulators of known signals, such as DLK. To accomplish this, we developed an
in vitro screen to identify injury signals required for induction of the pro-regenerative program.
We took advantage of the preconditioning phenomenon, in which a conditioning injury activates
the regeneration program and a second test injury assays its state (McQuarrie et al., 1977).
Traditionally, this paradigm is performed in vivo, but we and others have recently described an in
vitro version of this assay in which dissection of mouse dorsal root ganglia (DRG) neurons serves
as the preconditioning lesion (Frey et al., 2015; Saijilafu et al., 2013; Zou et al., 2009). Twentyfour hours later, the regeneration program is active, and we administer the testing injury via
replating of the neurons. Preconditioned neurons grow extensive neurites in a short time compared
to uninjured neurons. The major advantage that this assay has over the in vivo counterpart is that
injury signaling is induced in culture and so is amenable to pharmacological perturbations.
Importantly, drugs are present only during induction of the regeneration program, not during axon
sprouting or outgrowth.
We miniaturized this assay to develop a loss-of-function screening platform to identify
small molecules that inhibit induction of the axon regeneration program. From a 480-compound
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library, we found inhibitors of proteins with no known role in axon injury signaling and inhibitors
to several known injury signals. Our analysis focused on the most potent hits, heat shock protein
90 (HSP90) inhibitors, which blocked many of the molecular components of the pro-regenerative
program and the subsequent promotion of robust neurite outgrowth. These phenotypes mimic those
seen with loss of DLK. Because HSP90 is a chaperone that facilitates the activity of signaling
molecules, including kinases, we tested the hypothesis that HSP90 is required for axon injury
signaling as a chaperone for DLK (Schopf et al., 2017; Taipale et al., 2010). In support of this
hypothesis, we show that HSP90 binds DLK and is required for the stability of existing DLK
protein. We show that HSP90 regulates DLK levels in vivo in mice and Drosophila. Moreover,
we show that HSP90 is required for both DLK-dependent axon injury signaling and developmental
synaptic terminal overgrowth in Drosophila. Together, these data demonstrate that DLK is an
evolutionarily-conserved client of HSP90, axon injury signaling requires HSP90 activity, and that
a primary mechanism by which HSP90 facilitates injury signaling is to chaperone DLK.
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2.4 Results
2.4.1 A high-content loss-of-function screen identifies potent disruptors of the
axon regeneration program
Peripheral nerve injury stimulates axon regeneration by inducing a pro-regenerative
program. To identify mechanisms by which injury stimulates this program, we used a
preconditioning paradigm, in which a first conditioning injury activates the regeneration program
and a second test injury assays its state. While preconditioning is traditionally studied in vivo
(Neumann and Woolf, 1999; Shin et al., 2012a), recently, a number of groups have developed in
vitro preconditioning assays that take advantage of neuronal replating (Frey et al., 2015; Saijilafu
et al., 2013; Zou et al., 2009). In this method, dissection of the sensory neurons from the animal is
the first preconditioning injury and replating of the neurons 24h later is the test injury. Axons are
then allowed to grow for 18h with their length providing a readout for the efficacy of the
regenerative program. The major advantage that this assay has over its in vivo counterpart is that
injury signaling is induced in culture rather than in an animal, and so is amenable to
pharmacological perturbation. Chemical inhibitors can be applied during the 24h signaling phase
and then washed out before replating, the subsequent test injury (Fig. 1A). This enables selective
study of pro-regenerative signaling, not axon sprouting or elongation. We developed a loss-offunction screening platform to identify small-molecules that inhibit activators of the axon
regeneration program by miniaturizing a previously described replating assay (Frey et al., 2015).
Primary adult DRG neurons were plated, treated with test compounds, replated, stained, and
imaged in 96-well plates (Fig. 1B). We used a custom- high-throughput image analysis pipeline
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built in CellProfiler to quantify mean total neurite length per neuron for each well (Carpenter et
al., 2006) (Fig. 1C).
We previously demonstrated that pre-treatment with JNK inhibitor (JNKi) impairs
activation of the regenerative program leading to reduced axon growth following replating (Frey
et al., 2015). Here, we recapitulate this result in the 96-well format. We included JNKi-treated
(positive) and DMSO-treated (negative) control neurons on each screening plate (Fig. 1B).
DMSO-treated neurons successfully activated their regeneration program and grew long neurites
in the 18h test phase (Fig. 1D-E). JNKi reduced growth by ~60% compared to DMSO
demonstrating successful inhibition of the regeneration program. DMSO-treated neurons and
JNKi-treated neurons formed distinct distributions, demonstrating good separation between
control groups (Fig. 1F).
To identify other compounds that inhibit induction of the regenerative program, we
screened the ICCB Known Bioactives Library (480 compounds) at two doses (See Materials &
Methods). Hits were defined as follows: 1) the compound was non-toxic, and 2) the compound
caused at least a 2-fold reduction in growth compared to the negative control (Fig. 1G, dotted line,
growth cutoff = 0.5). This minimized the chance of obtaining false positives while maximizing
strong true positives (Fig. 1F, dotted line). We used final cell count to filter out toxic compounds.
Dead or dying cells are washed away during replating, and so wells with toxic compounds have
significantly fewer cells than controls. Thus, we defined a compound as toxic if it caused a 50%
or more reduction in final neuron count compared to controls (avg control cell count = 100 neurons
per well). Fifty-one unique compounds from the primary screen met the criteria for non-toxic
inhibitors of the regeneration program. Forty-five of these compounds were retested in the 96-well
assay and 35 compounds were hits a second time (Table S1). Of these, we obtained independent
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lots of the seven most novel compounds and successfully validated six using our original assay in
which the longest neurite per neuron is traced by hand (Frey et al., 2015; Valakh et al., 2015)(see
Materials & Methods).
The screen produced both known and novel hits (Fig. 1G, Table S1). Among the identified
compounds known to target proteins with previously characterized roles in injury signaling were
our positive control JNKi (SP-600125), rapamycin (mTOR inhibitor), and AG-490 (JAK2
inhibitor) (Abe et al., 2010; Qiu et al., 2005). We also found several compounds previously
implicated in axon outgrowth or growth cone formation: SB203580 (ERK inhibitor), SB202190
(p38 inhibitor), and roscovitine (CDK inhibitor) (Namgung et al., 2004; Verma et al., 2005;
Williams et al., 2005). A prior study showed that DRB (RNA polymerase inhibitor) and LY294002
(PI3 kinase inhibitor) both block induction of the regeneration program in vitro when used at doses
similar to those in our screen (Saijilafu et al., 2013). Although neither compound fell below our
hit threshold, both were extremely close, each reducing axonal growth by approximately 47%.
Despite finding many compounds expected from prior studies, we did not see effects with two
PKA inhibitors, H-89 and KT-5720, although PKA is required for injury signaling (Hao et al.,
2016; Qiu et al., 2002). In addition to these known hits, the screen also identified inhibitors of
proteins with no previously described role in pro-regenerative axon signaling: HSP90,
topoisomerase 1, casein kinases (CKs), sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a),
and proteases.

2.4.2 HSP90 inhibition prevents activation of the regeneration program
From this group of novel targets, we chose to perform a more detailed characterization of
the chaperone HSP90. Two HSP90 inhibitors, geldanamycin and its less toxic analog, 17-N41

allylamino-17-demethoxygeldanamycin (17AAG), were hits at both doses, with the high dose of
17AAG being the #1 hit in the screen. Moreover, there is no known role for HSP90 in axon injury
signaling or axon regeneration. In the manual replating assay in which the longest neurite per
neuron is imaged and quantified by hand, 1 µM 17AAG was sufficient to inhibit the regeneration
program over 5-fold compared to DMSO-treated controls (Fig. 2A-B). To assess whether the block
of axon regeneration was due to HSP90 inhibition, we tested a structurally distinct HSP90i,
ganetespib (GT), and found it also blocked preconditioned axon growth. As a comparison, we
inhibited the essential pro-regenerative kinase, DLK, with a recently-characterized potent and
selective compound, GNE-3511 (DLKi) (Patel et al., 2015), and found that it also strongly blocked
preconditioned axon regrowth. Although 17AAG did not score as toxic in the 96-well format,
before proceeding to mechanistic studies, we performed a more rigorous analysis of toxicity by
quantifying cell death. Live cells were defined as both positive for the mitochondrial potential
marker, TMRM, and negative for the cell death marker, YoPro. Neurons treated with either DMSO
or 17AAG for 24h displayed ~25% cell death, an expected percentage as not all cells survive
dissociation and plating (Fig. 2C-D). Those treated with the mitochondrial poison CCCP were
nearly all dead. Lastly, we asked if 17AAG-treated neurons retained the ability to grow neurites
long after drug washout to test whether 17AAG permanently abolished the ability of neurons to
grow neurites. We performed the replating assay as previously described, but instead of fixing the
neurons at 18h, we fixed at 72h, allowing ample time for neurons to reactivate their regeneration
program and grow long neurites. Indeed, both DMSO-treated and 17AAG-treated neurons grow
extensive neurites 72h after drug washout and replating (Fig. 2E). Collectively, these data
demonstrate that 17AAG blocks functional activation of the regeneration program and is not toxic
to adult sensory neurons.
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The axon regeneration program promotes axonal outgrowth via induction of a molecular
program that includes transcription factor activation, transcriptional induction of regenerationassociated genes (RAGs), and the production of axon growth-associated proteins (Abe and Cavalli,
2008). To explore how HSP90i inhibits the regeneration program, we assessed molecular
components of the regeneration program. Twenty-four hours after the conditioning injury, instead
of replating the neurons and measuring neurite outgrowth, we quantified the levels of
phosphorylated (activated) cJun (p-cJun), upregulation of regeneration-associated proteins
superior cervical ganglion 10 (SCG10) and growth-associated protein 43 (GAP43), and
transcriptional induction of two RAGs: Small proline-rich protein 1a (Sprr1a) and Galanin. cJun
is the transcription factor target of JNK and promotes axon regeneration (Raivich et al., 2004).
cJun phosphorylation increased ~5-fold between 1h and 24h post-plating (Fig. 3A-B). Neurons
treated with 17AAG only increased their p-cJun signal 1.6-fold. As a positive control, we tested
the effect of DLKi, since DLK is required for cJun phosphorylation following peripheral nerve
injury in vivo (Shin et al., 2012a). As expected, application of DLKi blocks the phosphorylation
of cJun in this system. Superior cervical ganglion 10 (SCG10) and growth-associated protein 43
(GAP43) are injury-induced cytoskeletal remodelers that are commonly used molecular markers
of regenerating axons (Frey et al., 2015; Shin et al., 2014). In neurons cultured for 24h, SCG10
and GAP43 increased approximately 7-fold (Fig. 3A&C) and 2.5-fold (Fig. 3A&D), respectively.
Surprisingly, neither 17AAG nor DLKi had a significant effect on the induction of these proteins.
Sprr1a and Galanin are injury-induced transcripts that each encode axon growth proteins (Bonilla
et al., 2002; Raivich et al., 2004). At twenty-four hours after plating, both Sprr1a and Galanin are
robustly upregulated (Fig. 3E). Neurons treated with 17AAG or DLKi fail to upregulate these
genes in response to axon injury. Hence, inhibition of HSP90 potently suppresses axonal
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outgrowth following injury, while blocking some but not all molecular components of the
regeneration program. HSP90 is not poisoning the entire regenerative program, but instead may
inhibit specific signaling pathways.

2.4.3 HSP90 binds DLK
HSP90 is a chaperone that regulates the stability, localization, or activity of signaling
molecules (Taipale et al., 2010). Given the large number of HSP90 clients, HSP90 may chaperone
multiple axon injury signals. The similarity of HSP90i and DLKi phenotypes led us to hypothesize
that DLK may be one such HSP90 client. Moreover, DLK is an essential pro-regenerative
molecule, and so this could be one mechanism by which HSP90 facilitates axon injury signaling.
A HSP90-client relationship is characterized by two key features: 1) the two proteins physically
interact, and 2) the client protein is degraded upon loss of chaperone function (Whitesell and
Lindquist, 2005). To investigate whether HSP90 binds DLK, we expressed flag-tagged DLK in
HEK-293 cells, which do not normally express DLK, prepared lysate, and immunoprecipitated
DLK using anti-flag antibody. Endogenous HSP90 was strongly enriched in the pull-down from
cells expressing DLK, but not in lysate from cells lacking DLK (Fig. 4A). Next, we sought to test
for this interaction in DRG neurons. We collected lysate from wildtype, uninjured DRG neurons
and immunoprecipitated endogenous DLK with an anti-DLK antibody. Endogenous HSP90 is coimmunoprecipitated with DLK, indicating that HSP90 and DLK interact in neurons under baseline
conditions (Fig. 4B). This finding is supported by a prior large-scale HSP90 interactome screen,
in which immobilized DLK captured HSP90 protein (Taipale et al., 2012). These data reveal a
HSP90-DLK interaction, supporting the hypothesis of a chaperone-client relationship.
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2.4.4 HSP90 is required for DLK stability
A second major hallmark of a HSP90-client relationship is loss of client stability during
chaperone inhibition. Thus, if HSP90 is a chaperone for DLK, HSP90i should lead to DLK
degradation. To test this, we measured DLK protein levels in DRG neurons with and without
HSP90 inhibition. Inhibition of HSP90 caused a 3.5-fold decrease in DLK protein after 8h
compared to treatment with DMSO vehicle (Fig. 5A-B). To test whether HSP90 chaperones other
MAPKs in the DLK pathway, we probed for the MAPKs downstream of DLK: MKK4 and JNK
(Walker et al., 2017). Consistent with published data, MKK4 and JNK protein levels were
unaffected by HSP90i (Citri et al., 2006; Taipale et al., 2012). There are two explanations for this
DLK phenotype: 1) existing DLK requires HSP90 for stability but is degraded when HSP90 is
inhibited, or 2) HSP90 functions as a traditional protein-folding chaperone to facilitate synthesis
of new DLK, and so HSP90 inhibition would block production of new DLK. For this latter
possibility to explain the rapid drop in DLK levels upon HSP90 inhibition, pre-existing DLK must
be rapidly turned over. If so, then DLK levels should decline to a similar extent when production
is blocked via an independent method, such as inhibition of protein synthesis. To test this second
model, we blocked protein synthesis with cycloheximide and assessed DLK protein levels. We
detect no significant change in DLK protein levels after 8h of treatment (Fig. 5C-D). To confirm
that cycloheximide was effectively blocking protein synthesis, we quantified the levels of the labile
protein SCG10 (Shin et al., 2012b; Walker et al., 2017) and saw a rapid, near-complete depletion
of SCG10 upon cycloheximide treatment. Thus, within an observation period of 8h, DLK protein
is stable in cultured DRG neurons. Upon application of HSP90 inhibitor, however, this existing
pool of DLK protein is rapidly lost.
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Next, we tested whether HSP90 is required for DLK stability in vivo. To acutely inhibit
HSP90 in mammals, we injected adult mice intraperitoneally with 75 mg/kg 17AAG or DMSO
vehicle three times a day for two days. Three hours after the final injection, we collected sciatic
nerve for protein analysis. The sciatic nerve of mice treated with 17AAG had ~50% less DLK
protein than nerves from DMSO-treated mice (Fig. 5E-F). This effect is not quite as dramatic as
in cultured neurons, possibly because 17AAG has a half-life of under 1h in plasma (Biamonte et
al., 2010). As seen in vitro, MKK4 and JNK protein levels were unchanged with HSP90i in vivo.
Together, these data demonstrate that HSP90 binds to DLK, and that HSP90 is required for DLK
stability both in cultured neurons and in vivo, supporting the hypothesis that DLK is a client of
HSP90. Further, within the DLK MAPK pathway, HSP90 specifically chaperones DLK.

2.4.5 The Drosophila Hsp90 ortholog, Hsp83, is required for DLK stability and
axon injury signaling in vivo
Having demonstrated that HSP90 function is required for axon injury signaling and DLK
stability in mammals, we turned to a Drosophila axon injury model for genetic validation and to
test whether this mechanism is evolutionarily conserved. As in mammals, Drosophila axon injury
triggers a DLK-JNK retrograde signal that activates a transcriptional regeneration program
(Klinedinst et al., 2013; Valakh et al., 2013; Xiong et al., 2010). We first asked whether levels of
the fly ortholog of DLK, Wallenda (Wnd), were affected by loss of Hsp83, the Drosophila ortholog
of HSP90. We expressed either RFP (control) or an RNAi transgene targeting Hsp83 in the nervous
system of larvae before harvesting the ventral nerve cord (VNC) for protein analysis. This RNAi
transgene is effective, leading to a ~5-fold reduction in Hsp83 protein levels (Fig. 6A&B). In
larvae expressing the Hsp83 RNAi transgene, there is a concomitant ~2-fold reduction in the levels
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of Wnd protein compared to control animals (Fig. 6A&C). Thus, loss of Hsp83 protein, like
inhibition of HSP90 in mammals, causes a loss of total Wnd protein in Drosophila.
To investigate the role of hsp83 in Drosophila axon injury signaling, we quantified injuryinduced JNK activation, a DLK-dependent phenomenon. JNK activity can be quantified in
Drosophila with a nuclear LacZ enhancer trap inserted into the JNK phosphatase puckered (pucLacZ), a JNK transcriptional target (Martín-Blanco et al., 1998). Normally, JNK activity is
minimal, leading to low expression of puc-LacZ. Injury-induced JNK activation drives a dramatic
increase in puc-LacZ (Xiong et al., 2010). We assessed the levels of puc-LacZ in larvae expressing
neuron-specific RNAi transgenes targeting either white (control), hsp83 or wnd. Twenty-four
hours after crushing motor neuron axons, there is an 8-fold increase in puc-LacZ in control neurons
(Fig. 6D-E). Knockdown of hsp83 or wnd strongly inhibits this response. Together, these data
demonstrate that Hsp83 is required for DLK stability and injury signaling in vivo and suggest the
DLK-HSP90 client-chaperone relationship is evolutionarily conserved from mammals to
invertebrates.

2.4.6 Hsp90 is required for developmental DLK signaling
Lastly, we tested whether HSP90 only stabilizes DLK in the context of injury, or whether
HSP90 is required for Wnd/DLK signaling more broadly. DLK is a critical protein not only for
axon regeneration, but also for neural development and neurodegeneration (Collins et al., 2006;
Farley and Watkins, 2018; Tedeschi and Bradke, 2013). We first assessed synapse growth in
Drosophila, a well-established phenotype for Wnd (DLK). Wnd/DLK drives the dramatic synaptic
terminal overgrowth in mutants for highwire (hiw), which encodes the ubiquitin ligase that targets
Wnd/DLK (Collins et al., 2006; Wan et al., 2000). At the Drosophila larval NMJ, hiw mutants
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display overgrown synaptic terminals with nearly 4 times as many synaptic boutons as wildtype
controls. As previously demonstrated, RNAi to wnd completely suppresses this phenotype. We
observed an equally potent suppression of the overgrowth phenotype when knocking down hsp83
(Fig. 7).
Finally, we asked if HSP90 is also required for developmental DLK signaling in
mammalian neurons following trophic factor withdrawal. Depriving embryonic DRG neurons of
nerve growth factor (NGF) triggers DLK-dependent cJun phosphorylation (Ghosh et al., 2011).
We pretreated neurons with either DMSO or HSP90i for 8h to deplete DLK prior to NGF
withdrawal. Three hours post-NGF deprivation, we assessed phosphorylated cJun. Similar to DLK
inhibition, HSP90 inhibition potently blocked cJun activation induced by NGF deprivation (Fig.
S1). Together with the data from Drosophila, these findings support the hypothesis that the
HSP90:DLK chaperone-client relationship impacts DLK signaling broadly and is not restricted to
axon injury signaling.
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2.5 Discussion
We performed a screen in primary adult mouse neurons to identify novel axon injury
signals and found that HSP90 is required for injury to induce the pro-regenerative program in
mouse and Drosophila neurons. Data from mechanistic experiments support the model that HSP90
promotes axon injury signaling, at least in part, by chaperoning DLK. In neurons, HSP90 binds
DLK, maintains DLK protein levels, and is required for DLK activity, such as JNK activation and
RAG induction following axon injury and synaptic overgrowth during development.

2.5.1 An in vitro preconditioning assay to screen for pro-regenerative axon
injury signals
Numerous screens have identified the transcription factors and RAGs that compose the
axon regeneration program and its output of cytoskeletal remodelers, axon growth molecules, and
guidance proteins (Chandran et al., 2016; Chen et al., 2011; Ghosh et al., 2011; Li et al., 2016;
Loh et al., 2008; Michaelevski et al., 2010; Nix et al., 2014; Smith et al., 2011; Usher et al., 2010).
These efforts have defined critical components of the axon regeneration process and have led to
promising translational results, including growth onto inhibitory substrates and CNS axon
regeneration in vivo (Chandran et al., 2016; Li et al., 2016). Here, we contribute to these efforts by
probing for injury-activated proteins that induce the pro-regenerative program in primary
mammalian neurons. We performed an in vitro screen that uses preconditioned neurite outgrowth
as a functional readout to test 480 compounds for the ability to prevent injury from activating the
pro-regenerative program. Our assay is unique in that it distinguishes components of the induction
phase, during which injury signals activate the program. Because this induction occurs in culture,
we can apply small molecule inhibitors and wash them out prior to the testing injury (replating).
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As a result, neurons regenerate neurites in the absence of perturbation; only the induction phase
was manipulated. Thus, this assay allows us to specifically target injury signals that induce the
pro-regenerative program and avoid affecting its products, such axon elongation or growth cone
proteins.
In this screen, we identified 35 compounds that reduced preconditioned neurite
regeneration by at least two-fold. The robustness of our screen is highlighted by hits that were
known injury signals. For example, AG490 (Janus kinase 2 inhibitor) and rapamycin (mTOR
inhibitor) were previously shown to inhibit preconditioning when injected into mice (Abe et al.,
2010; Qiu et al., 2005). Other hits, such as ERK and GSK3 inhibitors, support studies
demonstrating that genetic loss of either protein impairs mammalian axon regeneration (Perlson et
al., 2005; Saijilafu et al., 2013). Lastly, roscovitine, a CDK5 inhibitor and potent hit in our screen,
inhibited axon regeneration when applied after injury to the rat facial nerve in vivo (Namgung et
al., 2004). This study also described accumulation of CDK5 in regenerating axons. Our data
suggest an additional role for CDK5 as an injury signal that induces the pro-regenerative program.
Our p38 inhibitor (SB203580, SB202190) results provide mammalian data in support of previous
findings that demonstrate C. elegans and Drosophila p38 orthologs are required for axon injury
signaling (Klinedinst et al., 2013; Nix et al., 2011). In addition to HSP90, our screen also identified
many novel injury signal candidates, including topoisomerase 1 (TOP1), CKs, CDKs, and the
proteasome, although genetic validation is required before follow-up. Indeed, our capsazepine hit
suggested that TRPV1 is necessary to induce the regeneration program, however we found that
capsazepine still inhibited preconditioned neurite regrowth in TRPV1 knockout neurons,
demonstrating that this is an off-target effect. Interestingly, using a similar screening approach,
our group recently demonstrated that TRPV1 activation is sufficient to induce the regeneration
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program in small-diameter sensory neurons (Frey et al., 2018). Lastly, several hits, such as
curcumin or resveratrol, target dozens of proteins and thus provide little mechanistic information.
Indeed, the utility of this assay depends on the specificity of compounds screened.
Recently, a similar high-content screen was performed in zebrafish (Bremer et al., 2017).
Larval motor axons were axotomized via fin amputation before a 24h incubation with the ICCB
Known Bioactives library, the same library we used. Our assays differed in that our compounds
were only present during the induction phase of injury signaling, while in the Bremer et al. study,
compounds were present during the induction and outgrowth phases. Despite these differences,
both studies share many validated hits, including JNKi (SP600125), both p38 inhibitors
(SB202190, SB203580), and the CDK inhibitor, roscovitine. The concordant findings of these
known signals highlight the robust nature of both assays. One top hit shared by both screens was
the TOP1 inhibitor, camptothecin. Interestingly, their data suggest a role for TOP1 in promoting
Schwann cell survival following injury. Our in vitro assay is performed in the absence of Schwann
cells, leading us to hypothesize that TOP1 is also required in neurons to activate the proregenerative program. Lastly, several hits were not shared between the two screens, including
HSP90 which was toxic in the zebrafish screen and so was not analyzed. There are several reasons
that compounds may only have been hits in one screen, including technical differences such as the
presence of drug during the axon outgrowth phase in the zebrafish screen, the possibility of noncell autonomous effects in vivo, dosing and/or drug metabolism differences, or discordant
mechanisms of zebrafish and mouse axon injury signaling. Overall, both screens provide unique
advantages to identify new components of axon regeneration and injury signaling.
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2.5.2 A role for HSP90 in axon injury signaling
Traditional chaperones such as the HSP60, HSP70, and HSP100 families drive protein
folding, disaggregation, and proteolysis (Saibil, 2013). HSP90, however, facilitates maturation,
complex assembly, localization, and ligand binding of signal transduction proteins, including
kinases and nuclear receptors (Taipale et al., 2010). Given the role of HSP90 in many signaling
hubs, it is not surprising that HSP90 inhibitors were the top hits in our screen. While HSP90 has
many targets, the efficacy of HSP90 inhibition in our injury assays can be, in part, explained by
its regulation of DLK, an essential injury signal. Due to the number of clients, it is unlikely that
DLK is the only injury signal chaperoned by HSP90. Indeed, it was recently demonstrated that
HSP90 physically interacts with over half of the human kinome (Taipale et al., 2012). Nonetheless,
those authors found no interaction between HSP90 and many other injury-associated MAPKs,
such as leucine zipper kinase (LZK), MKK7, JNK1-3, and ERK1/2. Our data showing that MKK4
and JNK protein levels are unaffected by HSP90i agree with this published data (Fig. 5-B). In
addition, the fact that HSP90i does not significantly influence upregulation of SCG10 or GAP43
(Fig. 3) suggests that the role of HSP90 is confined to specific injury pathways. In future studies,
it will be interesting to identify any remaining HSP90 clients within the context of axon injury.
HSP90 has established roles in other neuronal contexts, namely the stabilization of
neurodegenerative protein aggregates, but also in neuronal polarization, axon pathfinding, and
neurotransmitter release (Benitez et al., 2014; Gerges et al., 2004; Luo et al., 2010; Wang et al.,
2013). Here, we describe a role for HSP90 in axon injury signaling and synapse growth. Other
heat shock proteins, HSP27 and HSP70, are upregulated following axon injury and localize to
axons, and HSP27 promotes axon outgrowth (Ma et al., 2011; Willis et al., 2005). Interestingly,
local translation of HSP90, HSP70, and HSP27 has been observed in injured DRG neurons in vitro
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(Willis et al., 2005). Thus, heat shock proteins likely play a vital role at many stages of axon
regeneration.

2.5.3 A novel mechanism of DLK regulation: HSP90 chaperone activity
Intense efforts to understand mechanisms of DLK regulation are driven by the central role
DLK plays in neuronal stress, development, axon regeneration, axon degeneration, and
neurodegenerative disease (Farley and Watkins, 2018; Ghosh et al., 2011; Le Pichon et al., 2017;
Miller et al., 2009; Pozniak et al., 2013; Shin et al., 2012a; Tedeschi and Bradke, 2013; Watkins
et al., 2013). Neuronal DLK can be activated directly by Ca2+ in C. elegans, cytoskeletal disruption
or cAMP/PKA in Drosophila and mammals, and by increasing DLK protein levels (Collins et al.,
2006; Hao et al., 2016; Valakh et al., 2015; Valakh et al., 2013; Yan and Jin, 2012). To date, the
best understood mechanism for regulating DLK is controlling its abundance. The best-known
regulator of DLK abundance is the E3 ubiquitin ligase, PHR1/highwire/RPM-1, which actively
targets DLK for degradation in mice, Drosophila, and C. elegans (Babetto et al., 2013; Brace et
al., 2014; Collins et al., 2006; Nakata et al., 2005). Upon injury, PHR1/highwire levels decrease
to promote increased DLK levels (Xiong et al., 2010). In addition, mammalian DLK drives a
positive-feedback loop in which its downstream MAPK, JNK, phosphorylates DLK to protect it
from ubiquitination via PHR1 (Huntwork-Rodriguez et al., 2013). Here, we identify HSP90 as a
new factor regulating DLK abundance: HSP90 is required to stabilize the existing pool of DLK
protein. Loss of HSP90 activity, either via inhibition in mice or genetic knockdown in Drosophila,
drives a sudden decline in DLK protein abundance. One major question that remains is whether
HSP90’s interaction with DLK is regulated. Our data suggest that the HSP90:DLK interaction
exists prior to injury, because in uninjured neurons, DLK and HSP90 coimmunoprecipitate and
HSP90i depletes existing DLK protein. Nonetheless, this interaction could be modulated by injury,
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thus protecting DLK from degradation by blocking ubiquitination via PHR/Highwire or promoting
the JNK-mediated feedback loop. Hence, our identification of an evolutionarily-conserved
mechanism by which HSP90 regulates levels of DLK protein adds to our molecular understanding
of DLK-dependent neuronal stress signaling and its regulation in development and disease.
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2.6 Materials and methods
Mice & primary DRG neuron culture
Adult CD1-IGS mice were purchased from Charles River. All experiments were performed
with male and female mice ages 8-12 weeks. Mouse husbandry was performed under the
supervision of the Washington University Division of Comparative Medicine. Adult dorsal root
ganglia (DRG) were isolated and pooled from cervical, thoracic, and lumbar spinal regions (Frey
et al., 2015). DRG were incubated for 15 min at 37C in a solution containing 0.35 mg/mL Liberase
Blendzyme (Roche), 0.6 mg/mL DNase (Sigma), and 10 mg/mL bovine serum albumin (Sigma).
DRG were then moved to 0.05% Trypsin-EDTA (Invitrogen) and incubated for 15 min at 37C.
Trypsin was removed and replaced with culture media consisting of DMEM (Invitrogen), 10%
fetal bovine serum (FBS, Invitrogen), and 100 U/mL penicillin, and 100 µg/mL streptomycin
(Invitrogen). DRG were dissociated via trituration with a 1 mL pipette tip and plated at a density
of 2-3 DRG/mL. Neurons were plated onto glass chamber slides (Fisher Scientific) or polystyrene
tissue culture plates (Corning). Prior to plating, plates or slides were incubated overnight with 10
mg/mL poly-D-lysine (Sigma) and then washed twice before being coated with 10 mg/mL laminin
(Sigma) for at least 2h. Neurons were cultured at 37C with 5% CO2. When neurons were cultured
for more than 24h, media was changed on day in vitro (DIV) 1 and 10 µM AraC (antimitotic,
Sigma) was added.
Embryonic DRG neurons were isolated from E13.5 CD1 embryos as previously described
(Valakh et al., 2015). All DRG were collected into cold DMEM and then placed into 0.05%
trypsin-EDTA for 20 min at 37C. DRG were dissociated with a 1 mL pipette and all cells were
resuspended in 60 µL. Neurons were plated as 2.5 µL spots on PDL/laminin-coated plates and
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cultured in Neurobasal medium (Invitrogen) with 50 ng/mL nerve growth factor (NGF, Harlan
Laboratories), 2% B27 (Invitrogen), 1 µM 5-fluoro-2’-deoxyuridine, and 1 µM uridine
(antimitotics, Sigma). Cells were cultured at 37C with 5% CO2 and media was changed on DIV2
and DIV5. To achieve enough protein for western blot analysis, neurons from 9 spots (roughly 16
DRG) were pooled for each condition.
Replating assay and neurite length analysis
Replating was performed as previously described (Frey et al., 2015). Media (including any
drug treatment) was removed from each well and cells were briefly washed with warmed DMEM.
DMEM was removed and replaced with 0.025% trypsin-EDTA and cells were incubated for 5 min
at 37C, 5% CO2. Trypsin was replaced with fresh culture media and the plate was gently washed
several times to release neurons before the entire cell suspension was replated onto PDL/laminincoated glass chamber slides. After 18h of culture at 37C and 5% CO2, neurons were fixed with 4%
paraformaldehyde (Electron Microscopy Services) in PBS for 20 min at room temperature.
Following a wash with PBS, cells were blocked with 0.1% Triton X-100 in PBS (PBST) with 10%
goat serum. Blocking solution was removed and replaced with fresh blocking solution containing
mouse anti-Tuj1 (βIII Tubulin) primary antibody (BioLegend, 1:500). Following overnight
incubation at 4C, primary antibody solution was removed, slides were washed 3x with PBS, and
then secondary antibody solution with goat anti-mouse A488 (Life Technologies, 1:1000) and
Hoechst 33342 (2 µg/mL, Life Technologies) was applied for 1-2h. Following antibody removal
and 3 more PBS washes, slides were mounted with Vectashield (Vector Laboratories) and a glass
coverslip, then sealed with clear nail polish. Tuj1-positive neurons were imaged under a 10x air
objective on a Leica DMI4000B microscope with a DFC7000T fluorescent camera. The longest
neurite of each neuron was traced using the ImageJ plugin, NeuronJ (Meijering et al., 2004).
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Within each experiment, two technical replicates (~100 cells each) were averaged to yield one
biological replicate. Data represents 3-8 independent experiments.
Automated replating assay, imaging, and neurite length analysis
Adult DRG neurons were plated into PDL/laminin-coated 96-well plates (Corning).
Neurons were plated at a density such that cells from one mouse filled two 96-well plates. The
inner 60 wells received cells while the outer-most wells were filled with water to reduce plate-toplate variability caused by evaporation. Replating, fixing, and staining was performed as
previously described but with a 12-span pipette. Plates were imaged on an Operetta High-Content
Imaging System (Perkin Elmer) with a 20x long-working distance air objective. The entirety of
each well was imaged, giving 51 images per well. The images were run through an automated
image analysis pipeline we built in CellProfiler (Carpenter et al., 2006) (Fig. 1C). In brief, the
pipeline identifies Hoechst-positive and Tuj1-positive neuronal somas and Tuj1-positive neurites.
It skeletonizes the image, subtracts the somas, and measures total length of the remaining neurites.
For each well, dividing the sum neurite length by the total neuronal soma count gave mean neurite
length/neuron. Within each plate, mean neurite length values were normalized to the average of
the 10 negative (DMSO) controls.
Pharmacology
The Screen-well ICCB Known Bioactives Library (Enzo) was purchased from the
Washington University High-Throughput Screening Core. The library consisted of 480
compounds dissolved in DMSO. We screened each compound at two concentrations between 100
nM and 100 µM, with most between 1 and 20 µM. Compounds were applied to cells immediately
after plating for 24h and were washed off before replating.
57

SP600125 (JNK inhibitor, Sigma) was used at 15 µM in all experiments. 17-allylaminogeldanamycin (17AAG, ApexBio) was used at 1 µM on adult DRG neurons and 5 µM on
embryonic DRG neurons. GNE-3511 (DLKi, MedChem Express) was used at 500 nM. Ganetespib
(ApexBio) was used at 15 nM. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP, Sigma) was
used at 50 µM. DMSO was the vehicle for all drugs in this study, except cycloheximide (Sigma),
which was dissolved into ethanol and applied at 500 µg/mL final.
To administer 17AAG in vivo, a 50 mg/mL stock of 17AAG was made in DMSO and mice
were injected intraperitoneally at 75 mg/kg. Mice were injected 3x/day for 2 days, with injections
roughly 4 hours apart and administered on alternating sides of the abdomen. Three to four hours
following the final injection, sciatic nerves were collected for western blot analysis.
Immunocytochemistry
As described above, neurons were fixed with 4% paraformaldehyde in PBS and blocked
with 10% goat serum in PBST. Cells were then incubated overnight at 4C with primary antibody
solution consisting of mouse anti-Tuj1 and either rabbit anti-GAP43 (Millipore, 1:500), rabbit antiphospho-cJun (Cell Signaling, 1:300), or rabbit anti-SCG10 ((Shin et al., 2012b), 1:5000). SCG10
antibody was purified from anti-SCG10 rabbit antiserum (Novus Biologicals) using the SulfoLink
Kit (Thermo). Following primary antibody removal, cells were washed with PBS and incubated
with secondary antibody solution containing Hoechst 33342 (2 µg/mL), goat anti-mouse A488
(1:1000), and goat anti-rabbit A568 (1:1000) in PBST + 10% goat serum (all from Life
Technologies). After 1-3h, secondary antibody solution was removed, slides were washed 3x with
PBS and then mounted with Vectashield and glass coverslips as described above. Images were
taken on a Leica SPE confocal microscope with a 40x oil immersion objective. 30-50 Tuj1-positive
neurons were imaged per group for each experiment. Gain was set based on the DMSO 24h group
58

so that intensity was not saturated. Nuclear (Hoechst-positive) p-cJun or somal (Tuj1-positive)
GAP43 and SCG10 intensities were quantified in ImageJ. Within one experiment, all images were
taken with the same gain and each group was normalized to the 1h baseline intensity. n=3-5
independent experiments were performed.
Cell death analysis
Adult DRG neurons were plated and treated with DMSO, 17AAG, or CCCP. After 22h,
cells were loaded with 50 nM Tetramethylrhodamine, methyl ester (TMRM), 1 µM Yo-Pro-1, and
500 ng/mL Hoechst 33342 (all dyes from Life Technologies). At 24h, the cells were placed in a
CU-501 live-imaging chamber (Live Cell Instrument) maintained at 37C and 5% CO2. At least
100 cells per group were imaged on a Leica DMI4000B microscope with a DFC7000T fluorescent
camera under a 20x long-working distance air objective. Bright field and UV channels were used
to identify 100 DRG neurons per group by their 10-70 µm diameter circular morphology and large
Hoechst-positive nuclei. Three independent experiments were performed.
Quantitative real-time PCR
qRT-PCR for regeneration-associated genes (RAGs) was performed as previously described (Frey
et al., 2015). Adult DRG neurons were cultured as previously described. At the time of plating,
neurons were treated with either DMSO, 1 µM 17AAG, or 500 nM GNE-3511. At 24h, lysate was
collected in Trizol Reagent (Invitrogen) and total RNA was isolated using chloroform extraction.
RNA was treated with RQ1 RNase-free DNase (Promega) for 30 min at 37C and then terminated
with RQ1 stop solution for 10 min at 65C. First strand cDNA synthesis was performed using the
qScript cDNA Synthesis Kit (Quanta Biosciences). For each group within one experiment, an
equal amount of DNase-treated RNA was used to obtain cDNA preparations of equal
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concentration. This cDNA was diluted and loaded in triplicate into a reaction plate with PerfeCTa
SYBR green FastMix Rox reagent (Quanta Biosciences). We confirmed the absence of genomic
DNA contamination using controls of nuclease-free water and non-reverse transcribed DNasetreated RNA. Amplification values were obtained using a QuantStudio 3 Real-Time PCR System
(Applied Biosystems) and analyzed using the ΔΔCT method with Gapdh as the loading control
(Schmittgen and Livak, 2008). Primers were validated previously using standard curves (Finelli et
al., 2013; Frey et al., 2015). Five to eight independent experiments were performed. For each RAG,
transcript levels were normalized to the 24h DMSO-treated group. In 3 runs (2 Sprr1a and 1
Galanin), RAG mRNA at 1h was undetectable and so was not used in the statistical analysis. For
example, Sprr1a was probed for in 8 independent experiments, but in two of them, Sprr1a
transcript from the 1h group was undetectable. The remaining 6 values were used for statistical
analysis in Fig. 3E. Primers: Galanin (Fwd: 5′-GCCCACATGCCATTGACAAC-3′, Rev: 5′CGGACAATGTTGCTCTCAGG-3′), Sprr1a (Fwd: 5-AGAGAACCTGCTCTTCTCTGAGT-3′,
Rev:

5′-

CTGGTGCAGCTGAGGAGGTA-3′),

and

Gapdh

(Fwd:

5′-

TGTGAACGGATTTGGCCGTA-3′, Rev: 5′- ACTGTGCCGTTGAATTTGCC-3′) (Finelli et al.,
2013; Frey et al., 2015).
Western blot
To analyze protein levels in cultured neurons, embryonic DRG neurons were cultured for
6 days as described above. Neurons from 3 littermate embryos were pooled for each experiment.
To assess 17AAG effect on DLK levels, groups were treated with either 5 µM 17AAG or an
equivalent volume of DMSO for either 4 or 8h. To measure turnover of DLK and SCG10,
cycloheximide was added for 4 or 8h. For all experiments, lysate was collected on ice with
Laemmli buffer with mini-cOmplete protease inhibitor (1x, Roche) and phosphatase inhibitor
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cocktail 3 (1:100, Sigma). Lysate was boiled at 100C for 10 min and run on a 4-15%
polyacrylamide gel (BioRad). Protein was transferred to a nitrocellulose membrane and then
blocked with 5% milk solution in Tris-buffered saline with 0.2% Tween-20 (TBST). Membranes
were incubated overnight at 4C in primary antibody solution consisting of 5% milk, TBST, and
one of the following antibodies: mouse anti-TUJ1 (1:5000, BioLegend), rabbit anti-SCG10
(1:2500,(Shin et al., 2012b)), rabbit anti-HSP90 C45G5 (1:500, Cell Signaling), rabbit antiGAPDH D16H11xp (1:1000, Cell Signaling), mouse anti-MAP3K12 N377/20 (1:500,
NeuroMab), rabbit anti-SEK1/MKK4 (1:1000, Cell Signaling), or rabbit anti-SAPK/JNK (1:1000,
Cell Signaling). Primary antibody solution was then removed, and membranes were washed 3x
with TBST before incubation with secondary antibody solution consisting of 5% milk in TBST
and HRP conjugated to either anti-rabbit or anti-mouse antibody (Jackson, 1:10,000). After 1-2h
of incubation, membranes were washed 3x and developed using Immobilon Western
Chemiluminescent Substrate (EMD Millipore). Membranes were imaged on a G:Box Chemi-XX6
(Syngene) and quantified using ImageJ. DLK band intensities of each lane were normalized to the
intensity of their corresponding TUJ1 loading controls. Final values are expressed as fold change
over time 0. Five independent experiments were performed. As necessary, membranes were
stripped with Abcam stripping buffer (15 mg/mL glycine, 1 mg/mL SDS, 1% Tween-20, pH 2.2)
following the manufacturer’s instructions (Abcam).
To measure DLK levels of mice in vivo, sciatic nerves were isolated into ice-cold PBS
where the epineurium was quickly removed. To minimize protein loss and degradation, nerves
were quickly transferred to lysis buffer consisting of RIPA (0.52% w/v deoxycholic acid, 1% v/v
NP40, 0.1% v/v SDS, 1X PBS), mini-cOmplete protease inhibitor (Roche), and phosphatase
inhibitor cocktail 3 (1:100, Sigma). Tissue was digested with a pestle, sonicated, and centrifuged
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at 4C for 5 min at max speed. Supernatant was collected and quantified with a BCA assay kit
(Thermofisher). Protein concentrations were equalized among groups in 1X Laemmli buffer, and
then analyzed by western blot as described above. DLK levels are represented as fold change over
DMSO controls.
To assess Drosophila protein levels, elav3E-Gal4 flies were crossed to either UAS-RFP
(control) or UAS-Hsp83-RNAi. Ventral nerve cords (VNCs) were isolated from third-instar larvae
and homogenized on ice in lysis buffer (100 mM NaCl, 100 mM Tris pH 8.0, 1 mM EDTA pH
8.0, 2 M urea, 1% v/v SDS, 20 mM Na3VO4, 1x Roche protease inhibitor) with a pestle. VNCs
from 10 genetically identical flies were pooled into one lysate to achieve sufficient protein
concentration. Gel electrophoresis and transfer were performed as described above. Membranes
were incubated overnight at 4C in primary antibody solution consisting of 5% milk, TBST, and
one of the following antibodies: rabbit anti-Hsp90 #4874 (1:300, Cell Signaling), mouse anti-bTubulin E7 (1:20, Developmental Studies Hybridoma), rabbit anti-Wallenda (1:800,(Collins et al.,
2006)). Secondary antibody incubation, development, and imaging were performed as described
above. Wallenda or Hsp83 levels are represented as fold over control animals. This experiment
was performed four times.
Co-immunoprecipitation
Human embryonic kidney (HEK293T) cells were cultured to 70-80% confluence and then
transfected via polyethylenimine with either empty FCIV (CMV promoter – gene of interest-IRESenhanced YFP (Venus)) vector (Araki et al., 2004) or FCIV containing flag-tagged DLK. Over
75% transfection efficiency 2 days after transfection was verified via the Venus reporter. Prior to
lysate collection, M2 anti-flag affinity agarose beads (Sigma) were blocked in 1.5% BSA overnight
at 4C. Two days after transfection, cells were gently washed with ice-cold PBS and then lysed on
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ice in co-immunoprecipitation (co-IP) buffer consisting of 1 mM EDTA pH 8.0, 10 mM HEPES
pH 7.4, 0.5% Triton, 1x mini-cOmplete protease inhibitor (Roche), 1mM phenylmethylsulfonyl
fluoride, and phosphatase inhibitor cocktail (Sigma, 1:100) in PBS. Lysate was sonicated and
cleared of cell debris by centrifuging at 13000 rpm for 5 min at 4C. A portion of lysate was saved
as Input and the remainder was incubated with anti-flag beads overnight at 4C with gentle shaking.
Beads were then washed 2x with coIP buffer, resuspended in 1x Laemmli buffer (containing SDS)
and boiled for 10 min at 100C to release bound protein. Following a 5 min centrifugation at 15,000
rpm, lysates were analyzed by SDS-PAGE and western blotting as described above. To
immunoprecipitate from embryonic DRG neurons, neurons were cultured in 6-well plates at a
density of 3 embryos per condition. Lysate was collected as described for HEKs and precleared
for 30 min with Protein-G Dynabeads (Invitrogen) at 4C. Lysate was incubated with mouse antiDLK antibody (Neuromab clone N377/20 1:100) or an equivalent amount of mouse anti-IgG
antibody

(Jackson

ImmunoResearch)

overnight

at

4C.

Next,

each

antibody

was

immunoprecipitated with Protein-G Dynabeads for 1h at 4C. Precipitates were washed, eluted into
sample buffer, and analyzed via SDS-PAGE as described above. DLK pull-down was probed for
with

rabbit

anti-MAP3K12

antibody

(Novus

Biologicals,

1:250).

Membranes

with

immunoprecipitated DRG proteins were developed using a WesternBright Sirius detection kit
(Advansta).
NGF Deprivation
Embryonic DRG neurons were cultured as previously described. Eight hours prior
to NGF withdrawal, DMSO or 15 nM ganetespib were applied. One hour prior to NGF withdrawal,
500 nM GNE-3511 was added to the DLKi group. Cells underwent a complete media change,
drugs were reapplied, and NGF was placed back into control wells while mouse NGF neutralizing
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antibody (Alomone Labs) was added to the NGF deprivation groups. Cells were fixed 3h after
media change and immunostained and imaged as described above. Within each experiment, two
technical replicates (~300 cells each) were averaged to yield one biological replicate. Data
represents 2 independent experiments.
Fly stocks
Flies were maintained at 25C on standard fly food. The following stocks were used in this
study: BG380-Gal4 (Budnik et al., 1996), puc-LacZ (Martín-Blanco et al., 1998), elav3E-Gal4
(Yao and White, 1994), dvglut-Gal4 (Daniels et al., 2008), and HighwireND9 (Wan et al., 2000).
Flies obtained from the Bloomington Stock Center included: UAS-RFP (#32218), UAS-wallendaRNAi (TRiP Collection #25396), UAS-hsp83-RNAi (TRiP Collection #33947), and UAS-whiteRNAi (TRiP Collection #33623).
Drosophila nerve crush assay
BG380-Gal4;puc-LacZ lines were crossed to flies expressing either UAS-white-RNAi
(control), UAS-Hsp83-RNAi, or UAS-wallenda-RNAi. Third-instar larvae were positioned with
their ventral surface up and segmental nerves were pinched through the cuticle for 5s with
Dumostar #5 forceps (Xiong et al., 2010). Larvae were transferred to a grape plate with activated
yeast paste added and kept alive for 24h at 25C. Larvae were then filleted open in PBS and fixed
in 4% paraformaldehyde for 20 min at room temperature. Larvae were washed with PBST and
blocked with 5% goat serum in PBST for 30 min. Larvae were incubated in primary antibody
solution consisting of rat anti-Elav 7E8A10 (1:50, Developmental Studies Hybridoma Bank),
mouse anti-LacZ 40-1a (1:100, Developmental Studies Hybridoma Bank), and 5% goat serum in
PBST overnight at 4C. After removing primary antibody, flies were washed 3x with PBST and
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incubated with secondary antibody solution containing goat anti-rabbit A488 (1:1000, Life
Technologies) and goat anti-mouse Cy3 (1:1000, Jackson ImmunoResearch Laboratories) for 1h.
After antibody solution was removed, larvae were washed 3x with PBST, equilibrated in 70%
glycerol in PBS, and mounted on slides with VectaShield. Ventral nerve cords were imaged at 40x
on a Leica TCS SPE confocal microscope. All images for each experiment were taken with
identical gain, which was set using “control injured” flies to avoid oversaturating LacZ signal. The
nerves crushed in this assay stem from motor neurons of the dorsal midline, a narrow strip of cells
centered in the ventral nerve cord. The nuclei of these cells were identified via elav staining in the
dorsal midline of the ventral nerve cord. Because puc-LacZ contains a nuclear localization
sequence, LacZ intensity was quantified in these nuclei for at least 7 animals and normalized to
uninjured neurons from control flies.
Drosophila synaptic overgrowth assay
To drive transgenic RNAi constructs in a highwireND9 mutant background, dvglutGal4,highwireND9 flies were crossed to UAS-Hsp83-RNAi or UAS-wallenda-RNAi lines. Thirdinstar larvae were filleted open and fixed in Bouin’s fixative for 10 min at room temperature. Flies
were stained as described above. To identify neuromuscular junctions (NMJs), larvae were probed
with rabbit anti-DVGLUT (1:10,000, (Daniels et al., 2008)). Secondary antibodies consisted of
goat anti-rabbit A488 (1:1000, Life Technologies) and anti-HRP-Cy3 (1:1000, Jackson
ImmunoResearch Laboratories) to label synaptic boutons and nerves, respectively. NMJs were
imaged at 40x on a Leica TCS SPE confocal microscope. The number of DVGLUT-positive
boutons were quantified from 18-23 NMJs at muscle 4 from at least 4 animals per genotype.
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Experimental design and statistical analysis
Prior studies have determined that a minimum sample size of 3 independent experiments
is required to reject the null hypothesis given α = 0.05 (Frey et al., 2015; Valakh et al., 2015;
Valakh et al., 2013). For cell culture experiments, one culture was considered one independent
experiment (biological replicate). For adult DRG cultures, one mouse gave sufficient cells for one
experiment. To achieve sufficient protein yield for western blot analysis, embryonic DRG neurons
were pooled from several littermate embryos to give n=1 independent experiment. For in vivo
mouse experiments, each mouse was considered n=1. Immunofluorescence (Figs. 3A-D, 6, Fig.
S1), CT values (Fig. 3E), and protein levels (Figs. 5-6) were all normalized to control or baseline
values, which are detailed in the respective sections above.
For Drosophila protein level analysis, each independent experiment is representative of 10
pooled ventral nerve cords. For puc_LacZ experiments, each animal was considered an
independent experiment. In the NMJ synapse overgrowth assay, each muscle 4 NMJ is confined
to its own hemisegment and is thus considered one independent experiment (Wan et al., 2000).
One animal provides approximately four muscle 4 NMJs to analyze.
Statistical tests were performed in Prism (GraphPad). All data are presented as mean ±
SEM, except for Fig. 1E, which is shown as mean ± SD to depict the well-to-well variability of
the screen. Experiments with two conditions (Figs. 1E, 5F, 6B, 6C) were analyzed for statistical
significance with a Student’s t-test. One-way ANOVA with a Tukey post-hoc test was used to
determine significance and correct for multiple comparisons of experiments with 3 or more groups
(Figs. 2B, 2D, 3B-E, 6E, 7B, Fig. S1). Two-way ANOVA with a Sidak post-hoc correction was
performed on data in Figs. 5B&D, as time and treatment were two independent variables. “*”,
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“**”, and “***” indicate p-values less than 0.05, 0.01, and 0.001, respectively, while exact values
are displayed in the figure legends.
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2.8 Figures

Figure 1. A loss-of-function screen identifies inhibitors of axon regeneration signaling in
vitro. (A) Primary adult DRG neurons were harvested and dissociated to activate axon injury
signaling (conditioning injury). Immediately after plating into 96-well plates, neurons were treated
with compounds. After 24 hours, the state of the regeneration program was assessed via a replating
(testing injury) and neurons were given 18h to regrow neurites in the absence of drug. (B) Each
plate consisted of 60 unique compound wells, 10 wells of the positive control, JNK inhibitor
(JNKi), and 10 wells of the negative control, DMSO. Water (blue) filled the edges of the plate to
reduce well-to-well variability. (C) Fixed plates were stained for Hoechst and neuronal Tuj1 and
imaged on a high-throughput microscope. For each well, total neurite length/cell was quantified
using a custom neurite tracing pipeline built in CellProfiler. Within each well, neurite lengths were
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summed and divided by the total cell count of the well. (D) Representative images of screen
controls. Scale bar = 50 µm. (E) Combined data from all control wells in the entire screen, mean
± SD. n = 238-240 for each group, unpaired two-tailed t-test, t=47.1, df=476, p<0.0001. (F)
Histogram of E with hit cutoff at 0.5 (dotted line) (G) Results from screening the ICCB Known
Bioactives Library at 2 doses. Hits are below 0.5 (dotted line).
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Figure 2. Hsp90 inhibitors potently block induction of the axon regeneration program. (A)
Low-throughput manual replating assay with the top screen hit, 17AAG (1 µM), a structurally
different HSP90 inhibitor [15 nM Ganetespib (GT)], and 500 nM DLK inhibitor GNE-3511
(DLKi). Scale bar = 100 µm (B) Quantification of A, mean ± SEM. Data represent the mean length
of the longest neurite per cell. Within each experiment, two technical replicates (~100 cells each)
were averaged to yield one biological replicate. n=3-8 independent experiments, 1-way ANOVA
w/Tukey’s multiple comparisons, DF=23, F=16.2, ***DMSO v. 17AAG p<0.0001, ***DMSO v.
GT p<0.0001, ***DMSO v. DLKi p=0.0008. (C) Adult DRG neurons cultured for 24h in the
presence of DMSO, 1 µM 17AAG, or 50 µM CCCP (positive control). Cells were loaded with the
cell death marker, YoPro, and the mitochondrial potential dye, TMRM, prior to live imaging. Scale
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bar = 10 µm (D) Quantification of C, mean ± SEM. A dead cell was defined as YoPro-positive
and TMRM-negative. n=3 independent experiments each with 100 cells, 1-way ANOVA
w/Tukey’s multiple comparisons, DF=8, F=75.3, DMSO v. 17AAG p=0.86, ***DMSO v. CCCP
p=0.0001, ***17AAG v. CCCP p<0.0001. (E) Neurons pretreated with DMSO or 1 µM 17AAG
for 24h and replated normally but given 72h to grow neurites rather than 18h. Scale bar = 100 µm.
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Figure 3. Inhibition of HSP90 blocks molecular components of the axon regeneration
program. (A) Adult DRG neurons plated and treated with DMSO, 1 µM 17AAG, 500 nM DLKi.
At 24h post-injury (hpi), adult DRG neurons were fixed and immunostained for pro-regenerative
markers (gray in top panels, red in merged) and neuronal Tuj1 (green). Scale bar = 20 µm. (B-D)
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Quantification for each marker, mean ± SEM. Fold intensity was normalized to neurons at 1 hpi
(“uninjured”). n=3-5 independent experiments with ~40 neurons quantified per group per
experiment, 1-way ANOVA with Tukey’s multiple comparison test. p-cJun: DF=17, F=15.3,
DMSO v. 1hpi p=0.0002, DMSO v. 17AAG **p=0.001, DMSO v. DLKi ***p=0.0006. SCG10:
DF=14, F=6.64, DMSO v. 1hpi p=0.01, DMSO v. 17AAG p=0.99, DMSO v. DLKi p=0.80.
GAP43: DF=14, F=7.15, DMSO v. 1hpi p=0.004, DMSO v. 17AAG p=0.099, DMSO v. DLKi
p=0.09 (E) Adult DRG neurons were dissociated, plated, and treated with 1 µM 17AAG, 500 nM
DLKi, or DMSO. At 24h post injury (hpi), RNA was collected, and regeneration-associated genes
were analyzed via qRT-PCR. Fold intensity was normalized to DMSO-treated neurons at 24hpi.
mean ± SEM. n=5-8 independent experiments, 1-way ANOVA with Tukey’s multiple comparison
test. Sprr1a: DF=26, F=19.8, DMSO v. 1hpi ***p<0.0001, DMSO v. 17AAG ***p<0.0001,
DMSO v. DLKi ***p<0.0001. Galanin: DF=18, F=14.0, DMSO v. 1hpi ***p=0.0005, DMSO v.
17AAG **p=0.003, DMSO v. DLKi ***p=0.0002.
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Figure 4. HSP90 binds DLK. (A) Empty vector or Flag-tagged DLK plasmids were expressed in
HEK-293 cells before DLK was immunoprecipitated with anti-flag beads. The precipitates were
probed for endogenous HSP90. Input represents 1% of total lysate collected prior to
immunoprecipitation. Data is from one representative experiment of n=5 individual experiments.
(B) Wildtype embryonic DRG neurons were cultured for 6 days, lysed, and incubated with either
anti-IgG or anti-DLK antibody to immunoprecipitate endogenous DLK. Precipitates were probed
for endogenous HSP90. Input represents 1.7% of total lysate collected prior to
immunoprecipitation.
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Figure 5. HSP90 inhibition in mouse neurons causes DLK protein degradation in vitro and
in vivo. (A) Embryonic DRG neurons were cultured for 6 days and then treated with either DMSO
or 5 µM 17AAG. Lysate was collected after 0, 4, or 8h of treatment and probed for DLK, JNK,
MKK4 and TUJ1 (loading control). To avoid excessive stripping, lysates were re-run to probe for
JNK or MKK4. The representative MKK4 bands are depicted with their respective TUJ1 loading
controls. (B) Quantification of A, mean ± SEM. Band intensity was normalized to the 0h timepoint.
2-way ANOVA with Sidak’s multiple comparisons test. DLK n=6 independent experiments, time:
DF=2, F=36.1, treatment: DF= 1, F=23.9, DMSO v. 17AAG at 4h ***p=0.0005, DMSO v.
17AAG at 8h ***p<0.0001. MKK4 n=4 independent experiments, time: DF=2, F=0.17, treatment:
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DF= 1, F=0.38, DMSO v. 17AAG at 4h p=0.99, DMSO v. 17AAG at 8h p=0.68. JNK n=3
independent experiments, time: DF=2, F=0.54, treatment: DF= 1, F=0.14, DMSO v. 17AAG at 4h
p=0.94, DMSO v. 17AAG at 8h p=0.98. (C) To determine if DLK is turned over within 8h, neurons
were treated with cycloheximide for the indicated times. Lysate was probed for DLK and the labile
protein SCG10 (protein turnover control) (D). Quantification of C, mean ± SEM. Band intensity
was normalized to 0h timepoint. n=5 independent experiments, 2-way ANOVA with Sidak’s
multiple comparisons test, time: DF=2, F=28.4, protein: DF= 1, F=51.6, DLK 0h v. 4h p=0.89, 0h
v. 8h p=0.83, SCG10 0h v. 4h **p=0.002, 0h v. 8h **p=0.002. (E) Adult mice were injected IP
with 75 mg/kg 17AAG or DMSO 3x/day for 2 days before collection of sciatic nerve lysate.
Representative images from 1 pair of mice. (F) Quantification of E, mean ± SEM. Band intensity
was normalized to DMSO controls. n=4 mice per condition, unpaired two-tailed t-test. DLK t=4.4,
df=6, **p=0.004, MKK4 t=0.25, df=6, p=0.81, JNK t=0.14, df=6, p=0.89.
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Figure 6. The Drosophila Hsp90 ortholog, hsp83, is required for DLK stability and injuryinduced JNK signaling in vivo. (A) Representative western blot of protein lysate from ventral
nerve cords of elav3E-Gal4;UAS-RFP (control) or elav3E-Gal4;UAS-hsp83-RNAi (hsp83-RNAi)
Drosophila 3rd instar larvae. Lysate was probed for the fly ortholog of DLK, Wallenda (Wnd), and
Hsp83. (B-C) Quantification of A, mean ± SEM. Band intensities were normalized to controls.
n=4 experiments per genotype, where each experiment consisted of 10 ventral nerve cords pooled
into one lysate, unpaired two-tailed t-test, hsp83: t=3.36, df=6, p=0.015, wnd: t=2.57, df=6,
p=0.042. (D) Ventral motor neurons of 3rd instar larvae were crushed with forceps and fixed 24h
later. Representative images of the ventral nerve cord midline of BG380-Gal4;puc-LacZ/UASwhite-RNAi (control), BG380-Gal4;puc-LacZ/UAS-hsp83-RNAi (hsp83), and BG380-Gal4;pucLacZ/UAS-wnd-RNAi (wnd) larvae stained for puc-LacZ expression (red) and Elav (green) to
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identify motor neuron nuclei. scale bar = 25 µm. (E) Quantification of D, mean ± SEM. n=7-13
animals per group, where a group is defined as one genotype + injury combination (i.e. 6 total
groups), 1-way ANOVA with Tukey’s multiple comparisons test, DF=49, F=39.0, ctrl uninjured
v. inj. ***p<0.0001, hsp83 uninj v. inj p=0.88, wnd uninj v. inj p=0.98.
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Figure 7. HSP90 is required for DLK-dependent synaptic terminal overgrowth at the
Drosophila neuromuscular junction. (A) Representative images of 3rd instar larva muscle 4
neuromuscular junctions (NMJs) of wildtype (WT), highwireND9 (hiw), highwireND9,dvglutGal4;UAS-wnd-RNAi

(hiw;wnd-RNAi),

and

highwireND9,dvglut-Gal4;UAS-hsp83-RNAi

(hiw;hsp83-RNAi) animals stained for the presynaptic bouton marker DVGLUT (green) and nerve
membrane marker HRP (red). Scale bar = 25 µm. (B) Quantification of A, mean ± SEM. n=18-23
NMJs total from at least 4 animals per genotype, 1-way ANOVA with Tukey’s multiple
comparisons test, DF=78, F=128.6, WT v. hiw ***p<0.0001, WT v. hiw;wnd-RNAi p=0.69, WT
v. hiw;hsp83-RNAi p=0.30.
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Table S1. Screen hits from the ICCB Known Bioactives Library
Compound

Description

17-Allylaminogeldanamycin

HSP90 inhibitor

multifunction antiviral,
anticancer, anti-inflammatory
Nocodazole
tubulin inhibitor
Geldanamycin
HSP90 inhibitor
Camptothecin
Topoisomerase 1 inhibitor
10-Hydroxycamptothecin Topoisomerase 1 inhibitor
Vinblastine
tubulin inhibitor
Thapsigargin
SERCA inhibitor
Tosyl-Phe-CMK (TPCK) Serine protease inhibitor
Latrunculin B
Actin inhibitor
inhibits casein and
5-Iodotubercidin
adenosine kinases, ERK2
multifunction anticancer,
Curcumin
inhibits NF-κB, STAT3, AP-1
Inhibits intracellular Ca2+,
TMB-8
nAChR, PKC
Trichostatin-A
histone deacetylase inhibitor
Taxol = Paclitaxel
microtubule stabilizer
Lycorine

Growth
Dose Manual
(Fold/DMSO) [µM] validation
0.03, 0.07

8.5, 1.7

0.12

3.1

0.06, 0.37
0.06, 0.06
0.07, 0.15
0.07, 0.14
0.07
0.09, 0.08
0.12, 0.34
0.12

16.6, 3.3
8.9, 1.8
14.4, 2.9
13.7, 2.7
5.5
7.7, 1.5
14.2, 2.8
12.6

0.12

2.5

0.16

13.6

0.17

11.6

0.2, 0.13
0.2

16.5, 3.3
5.9

0.23

14.1

pass

Roscovitine blocks axon elongation
(Namgung et al., 2004)

0.25
0.26, 0.2

13.3
7.1, 1.4

pass
control

Capsazepine
Ionomycin

TRPV1 inhibitor
Ca2+ ionophore

SP-600125

JNK inhibitor

0.3

22.7

SB-415286

GSK3 inhibitor

0.34

13.9

Resveratrol

0.34

2.2

0.37

1.1

Quercetin

multifunction anticancer
Kinase inhibitor (Broad
spectrum)
broad anti-inflammatory

0.38

14.8

SB 203580

p38 inhibitor

0.41

13.2

Mitomycin C

cross-links DNA
glutathione peroxidase
mimetic
Tripeptidyl peptidase II
inhibitor

0.42

15

0.42

18.2

0.43

11

mTOR inhibitor

0.43

5.5

EGFR inhibitor

0.44

14.2

0.45

16.8

0.46

11.4

Ala-Ala-Phe-CMK
Rapamycin
AG1478
Olomoucine
CITCO

Cdc2, CDK2, CDK5, ERK1
inhibitor
Constitutive androstane
receptor (CAR) agonist

SB 202190

p38 inhibitor

0.48

15.1

AG-490

JAK2 inhibitor

0.48

17

0.49

12

0.47

2.6

Cypermethrin
Chelerythrine

multifunction ion channel
inhibitor
multifunction PKC inhib.,
anti-inflam., antibacterial

pass

ERK1/2 are pro-regen. Injury signals
(Perlson et al., 2005)

Cdc2, CDK2, CDK5 inhibitor

Ebselen

pass

pass

Roscovitine

K252A

Role in axon regeneration?
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pass

fail

JNK is pro-regen. injury signal
(Lindwall et al., 2004)
GSK3 is pro-regen. injury signal
(Saijilafu et al., 2013)

p38 required for Ce and Dm axon
regen (Klinedinst et al., 2013; Nix et
al., 2011)

mTOR is required for axon regen (Abe
et al., 2010)
EGFR promotes substrate inhibition
(Koprivica et al., 2005)

p38 required for Ce and Dm axon
regen (Klinedinst et al., 2013; Nix et
al., 2011)
JAK2 is pro-regen injury signal (Qiu et
al., 2005)

Hits that were validated in the 96-well replating assay and did not cause overt toxicity (toxicity
defined as neuron count < 50% of controls). Two numbers in Growth and Dose columns signify
that compound was a hit at both doses tested. The 7 novel compounds tested in the manual assay
are designated by entries in the “Manual Validation” column. Manual assay = low-throughput
replating onto slides and quantification of longest neurite (see Methods). Ce = C. elegans, Dm =
D. melanogaster.
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Figure S1. HSP90 inhibition blocks cJun induction following NGF deprivation (NGFD).
Embryonic DRG neurons were cultured for 5 days, then treated with either DMSO or 15 nM
ganetespib (GT) for 8h before NGF was withdrawn from the culture medium. Cells were fixed 3h
post-NGFD. 500 nM DLKi was used as a positive control. Within each experiment, two technical
replicates (~300 cells each) were averaged to yield one biological replicate. n=2 independent
experiments, mean ± SEM, 1-way ANOVA w/Tukey’s multiple comparisons, DF=11, F=23.4,
**DMSO Ctrl v. NGFD p=0.001, GT Ctrl v. NGFD p=0.98, DLKi Ctrl v. NGFD p=0.99.
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Chapter 3: Discussion & Future Directions
This dissertation expands our understanding of axon injury signaling by defining a novel
molecular mechanism by which HSP90 chaperones DLK to enable activation of the proregenerative program. To accomplish this, I developed and performed the first high-content
functional screen for axon injury signals using primary mammalian neurons. This technique
expands the toolbox used to study axon injury signaling, which was limited to single-gene in vivo
assays or ‘omics profiling. Further, this work is the first to implicate HSP90 in neuronal injury.
Moreover, the data reveals a new mechanism of DLK regulation: HSP90 chaperone activity. DLK
is of central importance to many fields of neuroscience, including development and disease,
making the applications of this work wide-spread.

3.1 A fully in vitro preconditioning assay
The screen presented in this thesis used a fully in vitro preconditioning assay. Neurons are
dissociated from a mouse to induce the pro-regenerative program. Once it is fully active, we assess
the state of the program by injuring the neurons again via replating. This assay has been
demonstrated by us and two other groups (Frey et al., 2015; Saijilafu et al., 2013; Zou et al., 2009).
My thesis is the first to adapt this assay into a loss-of-function screening pipeline to identify new
components of axon injury signaling. Indeed, the novelty of this assay relies on the fact that drugs
are only present during injury signaling, not during outgrowth. This enables distinction between
early genes that induce the program and later genes that facilitate axon elongation.
In addition to HSP90, the screen produced many candidates that have no known role in
injury signaling, such as topoisomerase 1 (TOP1), casein kinases (CKs), cyclin-dependent kinases
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(CDKs), and the proteasome. Following genetic confirmation, it would be interesting to follow up
on some of these hits to define their role in axon injury signaling. For instance, TOP1 is an enzyme
that catalyzes the topological rearrangement of DNA to facilitate several processes, including
replication and gene expression (Plaschkes et al., 2005). TOPs function by creating single- (type
1) or double (type 2) stranded DNA breaks at specific locations (McKinnon, 2016). Interestingly,
TOP1 is highly expressed in mammalian neurons where it is required for transcription of
exceptionally long transcripts (>1 megabase) (King et al., 2013). Similarly, TOP2 is required to
express immediate-early genes triggered by synaptic activity, although these genes are relatively
average lengths (Madabhushi et al., 2015). The data in this thesis suggests that TOP1 is involved
in axon regeneration. Surprisingly, a similar screen found the same TOP1 inhibitors blocked axon
regeneration in zebrafish (Bremer et al., 2017). Their data, however, suggests a non-cell
autonomous role for TOP1 in promoting Schwann cell survival following injury. Our in vitro assay
is performed in the absence of Schwann cells, leading us to hypothesize that TOP1 is also required
in neurons to activate the pro-regenerative program. How could TOP1 be required to induce the
regeneration program? Since TOP1 is necessary for expression of long genes, one could first ask
if long genes are part of the pro-regenerative gene network. Or, perhaps in our chosen system of
sensory neurons, TOP1 is required for expression of shorter or average length RAGs. Ultimately,
it would be interesting to identify the TOP-dependent RAGs to begin to characterize the
mechanism of TOP in this paradigm. Overall, it is quite exciting that precise DNA topology may
be necessary for effective axon regeneration.
Additionally, the screen implicated CDKs in axon regeneration signaling. CDKs are
typically involved in cell cycle regulation, but some CDKs have roles outside of division,
particularly in post-mitotic cells (Malumbres, 2014). Indeed, some CDKs, such as CDK5, have
90

important roles in neuronal function (Lim and Kaldis, 2013). Our screen produced several
compounds that target CDK5, along with CDK1 and 2. Gene expression analysis demonstrates
that CDK1 and 2 are not expressed in adult DRG neurons, leading us to hypothesize that inhibition
of CDK5 is responsible for the phenotypes seen in our screen (Shin et al. unpublish data). CDK5
is induced by axon injury, localizes to growth cones, and inhibition of CDK5 impairs axon
regrowth in vivo (Namgung et al., 2004). Further, CDK5 and its neuron-specific activator, p35, are
required for cAMP-mediated growth of axons onto inhibitory substrates (He et al., 2016).
Collectively, these data describe a role for CDK5 in promoting axon outgrowth following injury.
In our assay, however, inhibitor is only present during the signaling phase of axon regeneration,
not during outgrowth. Thus, our data suggests that CDK5 plays an additional role in inducing the
regeneration program. To confirm this, one could test whether CDK5 inhibitors block RAG
induction or transcription factor activation following injury. Subsequently, it would be interesting
to identify the mechanism by which CDK5 and p35 drive injury signaling.
Further, one can imagine several follow-up screens that can take advantage of this new
technique. A logical step is to screen additional libraries. 480 compounds is rather small, and
larger, more specialized libraries exist, such as the GSK Published Kinase Inhibitor Set or the
MicroSource Spectrum library, which contains all currently FDA-approved drugs (Li et al., 2016).
Identifying that HSP90 inhibitors affect neuronal repair was surprising, as HSP90 inhibitors are
used in the clinic to treat various forms of cancer (Biamonte et al., 2010; Porter et al., 2010; Soga
et al., 2013). Thus, the data presented in this thesis also reveals unexpected new biology about
popular anti-cancer therapeutics. What other drugs similarly impact mechanisms of neuronal
homeostasis? Additionally, one can screen proteins, such as secretome libraries, to identify
extracellular regulators of injury signaling. For instance, it is known that secreted IL-6 from DRG
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neurons and nearby immune or Schwann cells can induce the regeneration program in DRG
neurons via JAK/STAT3 signaling (Cafferty et al., 2004; Cao et al., 2006). What other
extracellular signals can drive the pro-regenerative program?
Alternatively, one can adapt the replating assay to screen for modulators of specific injury
signaling pathways. For example, many pro-regenerative transcription factors, such as cJun,
ATF3, Smads, and countless others have been characterized by several groups (Bareyre et al.,
2011; Lerch et al., 2014; Lindwall and Kanje, 2005; Michaelevski et al., 2010; Moore and
Goldberg, 2011; Saijilafu et al., 2013; Tedeschi, 2011; Zou et al., 2009). Aside from JNK and
GSK3, many components upstream of these transcription factors remain unknown. Importantly,
activated states of these transcription factors can be assessed via immunostaining. One can culture
DRG neurons and apply compounds for 24h as described in this thesis. At 24h, however, rather
than replating, the neurons can be fixed and immunostained for transcription factors of interest.
Following high-content imaging and quantification, one can identify the compounds that block
transcription factor activation. Protein targets of the hits are likely new candidates required for
injury to induce that transcription factor. Given ample resources, the ideal approach is to screen a
library using both growth and immunofluorescent readouts. This will functionally elucidate much
of the upstream injury signaling that converges on transcription factor activation, a result which is
difficult to obtain from ‘omics profiling alone.
These proposed experiments rely on the replating assay in its current loss-of-function
(LOF) state. The assay can be modified, however, to identify compounds that induce the
regenerative state in the absence of injury. Our lab demonstrated that the regeneration program
fades after 4-7 days in vitro (DIV), as noted by the inactivation of pro-regenerative molecular
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markers (Frey et al., 2015). Indeed,
when DRG neurons are replated on

DIV0
Plate DRG

DIV4-7, they exhibit minimal growth

6 days

DIV6

DIV7

Apply drug

Replate

24 h

after 18h, similar to freshly dissected

18 h

neurons that have only been cultured
for 18h (Frey et al., 2015). Importantly,

Replated

the regeneration program can be Figure 1 Gain-of-function replating assay to identify
inducers of the axon regeneration program.

reactivated, either via replating or drug
treatment. For example, forskolin, a known pro-regenerative compound, can induce the
regeneration program in vivo (Qiu et al., 2002). To confirm this in vitro, DRG neurons are cultured
for a week, treated with forskolin, and replated 24h later (Figure 1). As with the LOF assay, drug
is washed out during replating and is not present during neurite outgrowth. Neurons pretreated
with forskolin exhibited preconditioned neurite outgrowth compared to those treated with the
control compound, DMSO (Frey et al., 2015). We have also demonstrated that cytoskeletal
poisons activate the regeneration program via DLK and are sufficient to precondition uninjured
neurons (Valakh et al., 2015). Thus, this assay can be used to screen for compounds that induce
the regeneration program. We recently published a screen that demonstrated the feasibility of this
approach. We screened the same ICCB Known Bioactives library and identified that TRPV1
agonists induced the regeneration program in small-diameter sensory neurons (Frey et al., 2018).
Mechanistic analysis determined that TRPV1 activation signaled through PKA, a known
regeneration kinase (Aglah et al., 2008; Hao et al., 2016; Qiu et al., 2002). Thus, it would be
interesting to screen additional, larger libraries to identify other molecules that can induce
preconditioning.
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3.2 A role for HSP90 in axon injury signaling
A complex network of signal transducers is required to drive the pro-regenerative program
(Mahar and Cavalli, 2018). Thus, it is logical that HSP90, a facilitator of numerous signaling
pathways, is essential for this process. I have demonstrated that DLK is a client of HSP90,
providing one possible mechanism by which injury signaling requires HSP90. Given the number
of HSP90 clients, it is very likely that HSP90 chaperones additional pro-regenerative signals.
Indeed, HSP90 interacts with over half of the human kinome, in addition to other signaling
molecules such as steroid receptors or transcription factors (Taipale et al., 2010; Taipale et al.,
2012). It would be interesting to determine the range of clients that HSP90 chaperones to facilitate
the regeneration program. To identify such substrates, one could pull down HSP90 in neurons and
perform mass spectrometry to identify all the HSP90 binding partners. Alternatively, one could
perform this with sciatic nerve lysate to identify in vivo interactions and obtain the axon-specific
HSP90 interactome. Lysate could be collected prior to and following sciatic nerve crush to test if
any interactions are affected by injury.
Interestingly, within kinase pathways, upstream kinases are more likely to be HSP90
clients. Several MAP3Ks, such as MLKs, are clients of HSP90, while many MAP2Ks and MAPKs,
including MKK4/7, JNKs, and ERKs, show no dependency on HSP90 (Citri et al., 2006). Our data
agree with this finding, in that stability of DLK, but not MKK4 or JNK, is dependent on HSP90
activity. Thus, I expect many upstream kinases to be identified by screening for axonal HSP90
clients. Excitingly, there are few other MAP3 or MAP4Ks implicated in pro-regenerative
signaling. Recently, the Lewcock group demonstrated that MAP4K4 drives DLK/JNK signaling
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following NGF withdrawal (Larhammar et al., 2017). It is unknown, however, if MAP4K4 drives
axon regeneration, yet it appeared as a strong hit in the HSP90-kinase interactome screen (Taipale
et al., 2012).
Lastly, one could identify the HSP90-dependent injury transcripts. This experiment would
prove difficult in vivo, however. In our hands, mice could tolerate 75 mg/kg 17AAG 3x/day for
two days. Many transcripts take several days post-injury to reach maximum expression (Costigan
et al., 2002; Li et al., 2015; Pan et al., 2003). Thus, one may need to alter the dose or only observe
early genes. Alternatively, one could perform this experiment in vitro by treating cultured adult
DRG neurons with HSP90i and collecting RNA over the following 24-48h.

3.3 The HSP90-DLK interaction
To establish DLK as a client of HSP90, I demonstrated that HSP90 binds DLK in
mammalian neurons and that inhibition of HSP90 rapidly depletes DLK protein. Nonetheless,
there are several outstanding questions regarding the HSP90-DLK interaction. One is whether
HSP90 is required for DLK signaling function. Because our axon injury readouts were over the
course of 24h, our data are unable to answer this question because HSP90i depletes DLK within
8h. How might one separate loss of DLK kinase activity from depleted protein levels? To test this,
one can examine DLK phosphorylation activity, which occurs rapidly. DLK will phosphorylate
MKK4 in embryonic DRG neurons within ten minutes following axotomy (Yang et al., 2015).
Thus, embryonic DRG neurons can be treated with HSP90i and axotomized. Lysate can be
collected after ten minutes and probed for phospho-MKK4. If HSP90 is required for DLK kinase
activity, one would expect a lack of phospho-MKK4 signal. Alternatively, to ensure preservation
of DLK levels, this experiment can be performed in a cell-free system, which lacks protein
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degradation machinery, such as the proteasome. Purified DLK can be obtained by
immunoprecipitating flag-tagged DLK from HEK293Ts (Hao et al., 2016). My data has
demonstrated that endogenous HSP90 will coIP with DLK, confirming that HSP90 will indeed be
present in the cell-free system. One can then test whether DLK is then able to phosphorylate
MKK4 in the presence of HSP90 inhibitor.
Another outstanding question is whether the interaction between DLK and HSP90 is
regulated by injury. Our data suggest that the HSP90-DLK interaction exists prior to injury,
because in uninjured neurons, DLK and HSP90 coimmunoprecipitate (coIP) and HSP90i depletes
existing DLK protein. Nonetheless, this interaction could be modulated by injury. For example,
HSP90 could increase affinity for DLK to increase DLK stability. Because a coIP is not
quantitative, it may be difficult to test if more HSP90 binds to DLK following axon injury.
Alternatively, one can examine the kinase adapter, Cdc37. Kinases are first bound the cochaperone Cdc37 before they are loaded onto the HSP90 homodimer (Taipale et al., 2012; Verba
and Agard, 2017). Interestingly, Cdc37 is phosphorylated prior to binding HSP90 (Verba et al.,
2016). After first confirming if Cdc37 co-IPs with DLK and HSP90, one can test whether Cdc37’s
phosphorylation state is influenced by injury. Perhaps its phosphorylation state increases following
axon injury and facilitates increased HSP90-mediated DLK stability. These data would provide a
more specific understanding of the mechanism by which HSP90 chaperones DLK to facilitate
injury signaling.
Alternatively, HSP90 could protect DLK from degradation by blocking ubiquitination via
PHR1/Highwire (Babetto et al., 2013; Huntwork-Rodriguez et al., 2013; Xiong et al., 2010). To
test if loss of HSP90 leads to PHR1/Hiw-mediated degradation of DLK, one can examine if Hsp83
RNAi can still deplete Wnd in hiw mutant flies. If Wnd levels are preserved, Hiw is required to
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mark Wnd for degradation following loss of HSP90. This would expand our understanding of the
molecular mechanisms of DLK regulation and establish a connection between two known
regulators of DLK protein, Hiw/PHR1 and HSP90.
Lastly, I have demonstrated that HSP90 is required for DLK function in developmental
contexts, including synapse growth in Drosophila and apoptotic signaling in embryonic DRG
neurons following trophic factor withdrawal. These data suggest that HSP90 chaperones DLK in
non-injury contexts, yet DLK is not limited to these two paradigms. It would be interesting to test
if HSP90 is required for other DLK-mediated neuronal phenotypes. Does HSP90i prevent RGC
apoptosis or embryonic DRG axon degeneration following axotomy? Can loss of HSP90 prevent
degenerative phenotypes seen in mouse models of ALS or Alzheimer’s disease (Le Pichon et al.,
2017)? Establishing whether HSP90 chaperones DLK in these neurodegenerative contexts may
benefit clinical approaches to these disorders.

3.4 Conclusion
Axons are fascinating, but fragile, cellular structures that network the nervous system. The
study of axon regeneration reveals fundamental mechanisms of neuronal homeostasis and is vital
to the development of nerve repair therapies. A central question in the field of axon regeneration
is how peripheral neurons detect axonal injury and activate the regeneration program. In this
dissertation, I characterize a new role for HSP90 in axon injury signaling and demonstrate that it
chaperones the essential neuronal stress sensor, DLK. To advance the discovery of new
components of axon injury signaling, I developed a high-content platform that functionally
identifies such proteins. This work enhances our understanding of the molecular mechanisms of
axon regeneration and establishes new tools to benefit the field.
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